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ABSTRACT 
Conventional solid dosage forms often lead to fluctuations which exceed the maxi-
mum safe therapeutic level and/or decline below the minimum effective level. It is 
recognised that many drugs for chronic administration should be administered on a 
schedule that maintains plasma drug concentration within the therapeutic window. 
Research in controlled release dosage forms aims at designing a system with a 
zero-order input (eg, ideally to deliver 8.33% of the dose per hour over a 12 hour 
duration), producing steady state plasma drug levels. Oral administration of drugs 
prepared as a controlled release formulation is extremely popular, and has attracted 
the attention of pharmaceutical scientists during the last decade. This has been due 
to the simultaneous convergence of various factors (eg, discovery of novel polymers 
and devices, better understanding of formulation and physiological constraints, expir-
ation of existing patents, prohibitive cost of developing new drug entities), involved 
in the development of these delivery systems. Controlled release oral products can 
be formulated as single or multiple unit dosage forms and the relative merits of 
multiple unit forms with their own rate controlling systems are well established. This 
work describes the development of a relatively inexpensive multiple-unit capsule 
dosage form of theophylline containing coated mini-tablets for drug delivery 
throughout the gastrointestinal tract. Preformulation studies on theophylline anhy-
drous included solubility and dissolution rate determinations. Techniques including 
X-ray powder diffraction, differential scanning colorimetry and infrared spectroscopy 
provided no evidence of true polymorphism after recrystallisation from various 
solvents. However, scanning electron micrographs showed the effects of solvent 
polarity and cooling rate on the size and shape of recrystallised particles. 
Theophylline granules were manufactured by using various binders and were film 
coated by fluidised bed technology with various proportions of ethylcellulose, con-
taining varying amounts of PEG 1540. In vitro release rates were dependent upon 
coating thickness and the proportion of PEG, which, being water soluble, created 
pores in the coating during dissolution studies as observed by a scanning electron 
microscope. However, substantial proportions of the drug remained unreleased from 
the granules. In order to overcome the problems of drug retention, plain granules 
were used and theophylline mini-tablets (3 mm diameter, weighing 15 - 20 mg) were 
manufactured and film coated with various Eudragits ® and other polymeric mixtures 
(soluble and insoluble). In vitro dissolution profiles from samples enclosed in hard 
gelatin capsules were determined using the USPXXI paddle apparatus in test media 
at pH 1.2 (HCI), pH 5.4 and 7.4 (phosphate buffers) at 37'C. Monitoring of in vitro 
theophylline release over 12 h, under identical hydrodynamic conditions, showed that 
the dissolution rate at pH 1.2 is substantially greater (95% of total drug content 
released in < 10 h) than that in phosphate buffers. The maximum release after 12 h 
was approximately 20 and 30% of total drug content of the tablet at pH 5.4 and 7.4, 
respectively. However, in vivo bioavailability after oral administration of tablets to 
rabbits corresponded to over 95% of total drug, compared with the same dose 
administered intravenously. The retarded drug release during in vitro dissolution in 
phosphate buffer was attributed to a possible interaction of phosphate ions with 
theophylline molecules at the tablet core-coat interface. These findings indicate that 
both rate and extent of theophylline release from the slow release coated mini-tablets 
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are highly sensitive to phosphate buffers. The data also emphasise the usefulness of 
an animal model for assessment of in vivo drug release and subsequent absorption 
during the development of modified release dosage forms. Mini-tablets were sub-
jected to isothermal and cyclic stresses to reach conditions for up to 6 months at 
different temperatures and relative humidity. The film integrity was maintained but 
ageing of the coating occurred which impeded dissolution. Reduced drug release was 
temperature related while the effect of relative humidi% was insignific~t. Encapsu-
lated mini-tablets (uncoated and coated with Eudragit RL and RS 2% w/w) equi-
valent to a 300 mg dose, were evaluated both in vitro and in vivo using beagle dogs. 
The pharmacokinetic parameters from single and multiple dose studies showed 
several advantages over Theo-Dur® 300 mg tablets. Precise dosage titration is 
possible by careful adjustment of the number of encapsulated mini-tablets. 
This multiple unit mini-tablet delivery system will allow for greater flexibility in 
dosage adjustment compared to the currently available preparations, allowing indi-
vidualised fine dose titration in those patients requiring therapeutic drug monitoring. 
The development of the multiple unit mini-tablet formulation appears to provide an 
optimal dosage form with maximum flexibility in respect of dose, duration range and 
ease of production. 
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CHAPTER ONE 
INTRODUCTION 
1.1 ORAL CONTROLLED RELEASE THEOPHYLLINE DOSAGE FORMS 
Theophylline (1,3-dimethylxanthine) is closely related chemically to caffeine and 
theobromine. These three methyla~ed xanthines occur in plants widely distributed 
geographically and grown specifically for beverage purposes such as tea (leaves of 
Thea sinensis), cocoa and chocolate (seeds of Theobroma cacao) and coffee (fruit of 
Coffea arabica). These beverages have central nervous system (CNS) stimulant 
actions that elevate mood, decrease fatigue and increase capacity for work. Theo-
phylline and caffeine are potent stimulants of the CNS. Although caffeine is probably 
more potent, theophylline however produces more profound and potentially more 
dangerous effects (Rall, 1980). Besides their stimulant action on the CNS, they also 
produce diuresis, stimulate cardiac muscle and relax smooth muscle of the bronchi, 
especially if the bronchi have been constricted in asthma. Theophylline has the most 
effective action on bronchial smooth muscle and because it also produces a definite 
increase in vital capacity, it is of value in the treatment of bronchial asthma. The 
bronchodilating effects of theophylline were first described as long ago as the 1920's. 
However in recent years there has been a resurgence of interest in the therapeutic use 
of theophylline principally as a result of increased knowledge of its cellular basis of 
action and its pharmacokinetics. 
The structural formula of theophylline is shown in Fig 1.1 There is a free proton on 
the N-7 position which makes theophylline a weak acid with a pKa of 8.8 at 23°C and 
8.3 at 37°C (Zuidema, 1983). 
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Fig. 1.1 The structural formula of theophylline 
H 
I 
Theophylline exists in both the anhydrous and monohydrate forms (Molecular weights 
180.2 and 198.2 respectively). The anhydrous form occurs as a white odourless 
crystalline powder with a bitter taste and a melting point of27O"C - 274°C. It is poorly 
soluble in water (1 in 120 at 25°C). A full physicochemical and analytical profile on 
theophylline is well documented (Cohen, 1975). To improve the solubility several 
so-called "salts" have been produced such as theophylline sodium glycinate, choline 
theophyllinate and theophylline ethylenediamine (aminophylline). These more so-
luble forms are used for parenteral preparations whereas for oral administration 
theophylline anhydrous or monohydrate may be used. 
Theophylline is readily absorbed after oral or rectal administration. In general the 
therapeutic range for theophylline has been recommended to be around 10 to 20 
pg/mL, however studies on asthmatic subjects have shown that the therapeutic effects 
of theophylline require a plasma concentration of at least 5 to 8 pg/mL (Jenne et ai., 
1972; Paifsky and Ogilvie, 1975; Ellis et ai., 1976.). Some reports indicate that the toxic 
effects become apparent at about 15 pg/mL and are frequent above 20 pg/mL (Zwillich 
et ai., 1975; Jacobs et ai., 1976). These toxic effects include nervousness, restlessness, 
insomnia, tremors, hyperesthesia and other signs of CNS stimulation (See Fig. 1.2). 
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Fig. 1.2 Rank-ordering of the actions of theophylline according to minimum plasma concentrations 
needed to elicit. (Adapted from Hendeles, L. et aI., Drug Intell. Clin. Pharm. 11, 12, 1977). 
Therapeutic strategies aim therefore at achieving and maintaining average plasma 
concentrations within a therapeutic range. Within these proper range levels, theo-
phylline is amazingly free of side effects. 
Theophylline is eliminated primarily by metabolism in the liver. There is considerable 
inter-subject variability in plasma concentration in different patients given the same 
dose. Although theophylline is highly bioavailable (F > 0.9; Hendeles et aI., 1977) 
differences in absorption and rates of elimination have been demonstrated (Hendeles 
et aI., 1978; Ogilvie 1978). For example the half-life of theophylline in young children 
averages about 3.5 hours, while 8 or 9 hours is more typical for adults (Gal et aI., 1978). 
Metabolic pathways of degradation are capacity limited and therefore the rate of 
elimination cannot increase proportionately to increases in drug dose. Morever the 
oxidative systems responsible for liver metabolism may be induced or inhibited. For 
example, hydrocarbons in cigarette smoke enhance metabolism, whereas certain 
drugs and diseases reduce elimination resulting in accumulation of the drug. In view 
of the wide range in elimination rates, it is often difficult to maintain steady state 
plasma concentrations of this drug, which has a relatively narrow therapeutic range. 
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The controlled release oral formulations have emerged as the most useful prepara-
tions for maintenance therapy in chronic conditions because of their ease of admin-
istration and greater therapeutic efficacy. However, physiological factors play a 
critical role when determining the suitability of using sustained release formulations. 
For instance, variable GI transit times will affect the time period over which the drug 
can be absorbed. Moreover, blockage of the GIT might allow release of the drug to 
occur over a small area and excessive localised concentrations and irritation could 
damage the surrounding tissue. In addition, the bioavailability of theophylline from 
sustained release oral formulations may be incomplete and variable (Upton et aI., 
1980; Spangler et al., 1978; Weinberger et al., 1978). 
Food intake affects gastric emptying (Fig.1.3; Fassihi, 1990) which may increase or 
decrease both the extent and rate of absorption (Melander et al., 1979: Singhvi et al., 
1982). Several workers have reported on the influence offood on the bioavailability 
of theophylline from controlled release preparations with varying conclusions (Lefeb-
vre et al., 1988; Hendeles et aI., 1985; Thompson et al; 1983; Leeds et al., 1982;Peder-
sen, 1981; Pedersen and Moller-Petersen, 1984; Sips et al., 1984; Jonkman et aI., 1981; 
Lagas and Jonkman, 1983; Macheras et al., 1987). 
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Fig. 1.3 Range of individual data points observed in subjects studied for gastric emptying of 
pharmaceutical dosage forms according to feeding conditions using gamma scintigraphy. 
(Key: F - fasted; LB - light breakfast (- 1500 kJ); HB - heavy breakfast (- 3600 kJ) 
(Data modified from Davis et aI., 1986) 
Therapeutic plasma levels must be maintained without repeated peaks and troughs 
characteristic of conventional dosage forms. Some patients may have subtherapeutic 
concentrations, while in others the drug concentration may lie above the reCOill-
mended values. This interpatient variability is due to differences in absorption and 
different rates of elimination. Elimination is also influenced by other factors such as 
age, smoking history, diet, concomitant diseases and the concurrent use of certain 
other drugs. 
In particular, the 12-hour controlled release oral dosage preparations of theophylline 
have been in recent years the focus of great attention. Only patients with a frequently 
recurring or continuous symptoms are likely to benefit from a controlled release 
dosage form. In these patients a constant serum level is likely to provide greater 
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stability of the hyper-reactive airways that characterises this disease than fluctuating 
concentrations. Rapid release formulations administered at 8 h intervals to patients 
with rapid elimination will result in unacceptably large fluctuations. A product with 
complete and slow enough absorption provides more constant serum levels with larger 
dosing intervals than rapid release f?rmulations (Weinberger et al., 1981). 
There are several commercially available slow release theophylline preparations with 
proven efficacy. However they may differ to clinically important degrees in the extent, 
rate and consistency of absorption (Weinberger et al., 1978; Fagerstrom and Heintz, 
1983). Most of the currently available commercial controlled release oral theo-
phylline preparations are given twice daily (12 hour preparations), but there are a few 
which are given once daily (24 hour preparations). The oral controlled release 
theophylline preparations which are currently available in South Africa include the 
following: 
Chronophyllin ® Capsules 
EuphyUin Retard® Tablets 
Microphyllin SR ® Capsules 
Nuelin SA ® Tablets 
Somophyllin CRT®Capsules 
Theo-Dur® Tablets 
Theo-Dur® Sprinkle Pellets 
Once daily 
Twice daily 
Twice daily 
Twice daily 
Twice daily 
Twice daily 
Twice Daily 
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The design of the above proprietary products are subject to patent rights and therefore 
precise details thereof are not known. However they release the drug by mechanisms 
which will be discussed in the following section of this Chapter. 
Dosage regimens have to be carefully adjusted according to particular patient needs. 
Although oral controlled release theophylline dosage forms are designed to control 
drug release rate, individual titration of the dose rate is still necessary. However the 
presently available dosage units cannot be divided into sub-units to meet precise 
individual needs. This is especially the case with encapsulated pellets, although some 
tablet formulations may be bisected or trisected. The modern sophisticated methods 
of therapeutic drug monitoring now available has made precise individual dose 
titration possible. The need exists therefore for a multiple-unit dosage form which 
can provide precise dosage titration for a particular patient by accurate adjustment of 
the dose. 
The objectives of this study were to develop an oral controlled release theophylline 
dosage form which would meet with the following requirements. 
1. Maintain plasma concentrations within the therapeutic range (10 - 20,uglmL) for 
maximum periods oftime during successive dosage intervals. Plasma fluctuations 
should be minimal without the concentration decreasing to sUbtherapeutic levels 
or increasing beyond the maximum safe concentration where toxic symptoms are 
experienced. 
2. The dosage form should provide maximal bioavailability of the drug. 
3. The design of the dosage form should be such that there is minimal danger due 
to "dose dumping". 
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4. Individualised dose titration must be possible to meet patient's precise needs by 
careful adjustment of the dose required. 
5. The preparation must have maximum stability on storage during the shelf life. 
Changes in drug release profile after the shelf life should be insignificant. 
6. The dosage form should be simple in design and hence as inexpensive as possible. 
In this thesis the author has carried out work directed toward achieving these objec-
tives. A novel multiple-unit capsule dosage form containing mini-tablets, with each 
unit providing a precise dose of theophylline in the form of an extended release drug 
delivery system, has been proposed. The dosage form will be designed, manufactured 
and its in vitro-in vivo performance evaluated. 
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1.2 PRINCIPLES AND RATE CONTROLLING MECHANISMS OF CONTROL-
LED RELEASE DRUG DELIVERY SYSTEMS 
Controlled release of a drug from a delivery system can be established by chemical or 
physical methods. The chemical methods are based on the chemical or biological 
degradation of polymers. For example in the pendant-chain system, in which a drug 
is chemically attached to the backbone of a polymer, the drug is gradually released 
from the polymer by hydrolysis or enzymatic cleavage (Kim et aI., 1980). The 
overwhelming majority of the marketed oral controlled release systems are based on 
physical principles (dissolution, diffusion, osmosis and desorption) and can be cate-
gorised as those in which drug release is: (i) regulated by dissolution of excipients, (ii) 
governed by diffusion of the drug; (iii) provided by osmotic pressure; (iv) the result 
of a desorption reaction from a drug-resin complex; or (v) based on other physical 
principles e.g. relaxation, swelling, erosion etc. 
The mathematical theory of diffusion in isotropic substances is based on the hypo-
thesis that the rate of transfer of diffusing substance through unit area of a section is 
proportional to the concentration gradient measured normal to the section, i.e. 
F = - D aC/ax, (Ll) 
F is the rate of transfer per unit area of section, C the concentration of diffusing 
substance, x the space coordinate measured normal to the section, and D is the 
diffusion coefficient. 
The fundamental differential equation of diffusion in an isotropic medium is derived 
from equation (Ll), a simplified form of which is, 
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aC Dic 
= 
t 1.2) 
assuming diffusion to be one-dimensional, i.e. a gradient of concentration along only 
the x - axis. Expressions (1.1) and (1.2) are usually referred to as Fick's first and second 
laws of diffusion. Various mathematical solutions to equation (1.2) have provided 
useful quantitative methods for studying the drug release phenomena. The Fickian 
diffusion of a soluble drug from monolithic delivery systems may be expressed by 
equation (1.2) where it is assumed that the diffusion coefficient of the drug, D, is 
concentration-independent. Release rate from monolithic devices also depends upon 
their method of preparation. Within this context at least two different types of devices 
can be envisioned. In the first type the polymeric device is soaked in a drug solution 
until the polymer is saturated with drug. In the second type, drug is dispersed directly 
in a polymer to form a dispersed drug delivery system. Under perfect sink conditions 
diffusion through a plane sheet of thickness I, at x = 0, where region 0< x < I is initially 
at a uniform concentration Co, and the surfaces are kept at a constant concentration 
C1, the solution of equation (1.2) is given (Crank, 1956) by: 
Mt 
Moo 
= 1- L 
n=o 
8 2 2 2 I -D(2n + 1) :n; t/41 
(1.3) 
where Mt denotes the total amount of diffusing substance at time t, Moo is the 
corresponding quantity after infinite time, and n is an integer. Equation (1.3) can be 
approximated over the initial portion of the release profile. 
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Mt (Dt) 1/2 
=4 -
Moo ",12 
for 0,; Mt ,;0.6 
Moo (1.4) 
However, if a drug is dispersed as such in the polymer phase (second type), the release 
kinetics may be altered when the total amount of the dispersed drug per unit volume 
of matrix (A) exceeds the amount which is necessary to provide a saturated solution 
(Cs) after contact with the medium. The release kinetics for this case have been based 
on the classical expression derived by Higuchi: 
(1.5) 
where Q is the amount of drug released per unit area, D the diffusion coefficient of 
drug in the homogeneous matrix phase, Cs the solubility of drug in the matrix phase, 
t is time and A the total amount of drug present per unit volume of matrix. 
When A> > Cs, equation 1.5 reduces to: 
Q = (2ADsCst)1I2 (1.6) 
Therefore, plots of the drug release under sink conditions versus the square root of 
release time should give a straight line if Fickian diffusion is the predominant 
mechanism of release. 
In many experimental situations, including the case of polymeric hydrogels and 
heterogeneous-matrix systems, the mechanism of drug diffusion deviates from that 
derived for pure monolithic systems. The increasing release rates from heterogeneous 
multiphase structure systems may be considered as an approach to achieving a 
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zero-order (time-independent) release rate. In these cases, a general equation, which 
is an extension of equation (104), can be used: 
Mt = ktO 
Moo (1.7) 
where Mt/M 00 is the fraction of drug released at time t, k is a kinetic constant 
characteristic of the drug/polymer system, and n is an exponent which characterises 
the type of release mechanism operative during the dissolution process. Release rates 
can be fitted to the equation (1.8), which is obtained upon differentiation of equation 
(1.7): 
dMt = nAkt"-l 
sdt (1.8) 
where "s" is the releasing surface area, and A is the initial concentration of drug in the 
polymer matrix. Table 1.1 summarises the general dependence of n on the diffusional 
mechanisms (Korsmeyer et aI., 1983). 
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Table 1.1 
ANALYSIS OF DIFFUSIONAL RELEASE MECHANISMS 
Value of 
exponent (u) 
0.5 
0.5 <n< 1.0 
1.0 
n> 1.0 
Release Kinetics 
Fickian diffusion 
Anomalous (non-Fickian) 
diffusion 
Case II transport 
Super Case II transport 
Time-dependence of 
solute release 
rate (dMJdt) 
zero-order (time-
independent) release 
tn -1 
Many matrix formulations are based on a published model (Higuchi,T., 1963), and the 
ensuing square root law has been used to describe drug release from inert matrices 
(Fessi et aI., 1978; Roseman, 1975; Fassihi, 1987). In non-swelling monolithic devices, 
release rates of solutes suspended in the matrix decline throughout the dissolution 
process. This is a result of both increasing diffusional pathlength and decreasing 
surface area with time. In addition to the pure monolithic systems, devices possessing 
other structural features have been suggested and prepared, such as the laminated 
and hemispherical matrix systems (Paul, 1985; Hsieh et aI., 1983), and the multiphase 
cross-linked polymeric hydrogel systems (Law et aI., 1986). Of particular interest is 
the potential use of these systems as inexpensive devices for delivery of drugs and 
other bioactive compounds at controlled, and perhaps time-independent, rates. 
The other rate controlling mechanisms in slow release preparations are based on (i) 
the osmotic pump, and (ii) ion- exchange systems. 
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(i) Osmotically controlled systems 
A publication by Theeuwes, 1975 has reported on the application of osmotic pressure 
in controlled release systems. These dosage forms have a semipermeable membrane 
and osmotic pressure provides the driving force to generate controlled release of 
drugs. The semipermeable membra.ne is permeable to water but not to the drug. A 
tablet containing a drug core surrounded by such a membrane is shown in Fig. 1.4. 
When the device is exposed to water, water will flow into the tablet due to the osmotic 
pressure difference. The rate of flow, dV/dt, of water into the device can be expressed 
dV = kA (l"" - AP) 
dt h 
(1.9) 
where k is the membrane permeability, A is the membrane area, h is the membrane 
thickness, JJ. n: is the osmotic pressure difference, and A P is the hydrostatic pressure 
difference. 
There are two types of this system (See Fig. 1.4). 
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TYPE A 
WATER 
TYPE B 
RIGID SEMIPERMEABLE 
.--;;::=.::::::-. / MEMBRANE 
WATER 
OSMOTIC CORE 
CONTAINING DRUG 
RIGID SEMIPERMEABLE 
OSMOTIC CORE WITHOUT 
FLEXIBLE MEMBRANE DRUG 
Fig. 1.4 The two types of osmotically controlled systems.Type A contains an osmotic core with drug, 
while type B contains drug solution in a flexible bag with the osmotic core surrounding. 
Type A contains the drug in the form of a solid core associated with electrolyte. The 
electrolyte is dissolved by the incoming water providing the high osmotic pressure 
difference. On the other hand, type B contains the drug solution in an impermeable 
membrane within the device with the electrolyte surrounding the bag. Both types 
have single or multiple holes bored through the membrane to allow drug release. In 
type A, the high osmotic pressure can be relieved only by pumping drug containing 
solution out of the orifice. Similarly with type B, the high osmotic pressure will cause 
compression of the inner membrane and drug is pumped out the hole. In this case 
the hydrostatic difference becomes negligible and equation 1.9 becomes 
dV = leA (t.,,) 
dt h (LlO) 
The flow rate of water into the tablet therefore is governed by permeability, area and 
thickness of the membrane. On the other hand, the rate of drug leaving the orifice, 
15 
dMJdt, is equivalent to the fldw rate of incoming water multiplied by the solution 
concentration of drug, Cs, within the device. 
dM = dVCs 
dt dt 
(1.11) 
With solid drug/electrolyte systems, the size and number of laser drilled holes are the 
rate-limiting factors for drug release. 
There are certain orally administered osmotic systems without a hole. The osmotic 
pressure causes the tablet to burst, causing the drug to be rapidly released. 
The advantages of osmotically controlled systems include: 
1. Zero-order release is obtainable. 
2. Reformulation is not required for different drugs. 
3. Drug release is independent of the environment of the system. 
There are also some disadvantages: 
1. The systems are much more expensive than the more conventional counterparts. 
2. Quality control is more extensive than most conventional tablets. 
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(ii) Ion-Exchange Systems 
These systems generally utilise resins composed of water- insoluble cross-linked 
polymers, which contain salt-forming functional groups in repeating positions on the 
polymer chain. The drug is bound to the resin and is gradually released by exchanging 
with appropriately charged ions in cOntact with the ion-exchange groups (Motycka et 
al.,1985). 
Resin + - Drug- + X- goes to Resin + - X- + Drug' 
or 
Resin- - Drug + + Y + goes to Resin' - Y + + Drug + 
where X" and y+ are ions in the GIT. 
The drug diffusion rate out of the resin is controlled by the area of diffusion, diffusional 
path length and the rigidity of the resin, which is a function of the amount of 
cross-linking agent used to prepare the resin. 
This system has advantages for drugs that are highly susceptible to degrad,ation by 
enzymatic processes since it offers a protective mechanism, by temporarily altering 
the substrate. However since the release rate is proportional to the concentration of 
the ions present in the area of administration, this approach to sustained release is 
rather limited. Moreover the release rate of drug can be affected by variability in diet, 
water intake, and individual intestinal content. A modification is the Pennkinetic 
system in which the drug-resin complex is embedded in a granule of polyethylene 
glycol which is then coated with ethylcellulose (Raghunathan et al., 1981). The 
hydrophobic polymer coat governs the rate of drug availability. 
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These principles and mechanisms of controlled release drug delivery will be impli-
cated in the design and development of the proposed theophylline dosage forms in 
this thesis. 
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CHAPTER TWO 
PREFORMULATION STUDIES 
Preformulation studies should be carried out on a drug substance prior to its devel-
opment into different dosage forms in order to optimise those physical and chemical 
properties that are considered important for the formulation of a stable, effective and 
safe dosage form (Shami et al., 1976; Nyqvist, 1986). Consideration should also be 
given to possible interactions with various other components intended for use in the 
final product. Studies should be made of such aspects as polymorphism, crystal size 
and shape, pH solubility profile, solubility, dissolution and stability. These factors 
could have a significant effect on the bioavailability of the dosage form. The inte-
grated information obtained from the preformulation studies is useful in selecting the 
best form of the drug for presentation in dosage form. The studies performed on 
theophylline anhydrous are described, together with discussions of the results. 
2.1 POLYMORPHISM 
In their review article, Haleblian and McCrone (1967) define a polymorph as a "solid 
crystalline phase of a given compound resulting from the possibility of at least two 
different arrangements of the molecules of that compound in the solid state". A 
compound may have the ability to crystallise as more than one distinct crystal species, 
termed polymorphs, being different in structure and properties as the crystals of two 
different compounds. The different properties will include variations in melting 
point, solubility, dissolution, crystal shape, density, hardness and optical properties. 
Such changes could produce significant modification of performance properties such 
as the stability and bioavailability of the dosage form. A different polymorph of the 
same compound may possess higher solubility and dissolution rates which would result 
in improved rates and extent bioavailability. In formulating a sustained release 
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preparation, where dissolution rate is a critical factor, a knowledge of the existence 
of other possible crystal fonns is essential. 
Different polymorphs may be prepared by manipulation of conditions of crystal-
lisation such as solvent, temperature and rate of cooling. In order to investigate 
whether theophylline anhydrous waS capable of polymorphism, the drug was recry-
stallised from several different solvents with varying polarities and at different cooling 
rates. 
2.1.1 Materials, Methods and Equipment 
Theophylline Anhydrous B.P. was used as received from Holpro Chemical Corpora-
tion (Pty) Ltd. The solvents used were ethyl alcohol (95%), chloroform, acetone and 
n-propyl alcohol. All were of analytical grade. Quantities of theophylline anhydrous 
were dissolved with gentle heat in sufficient of each solvent to produce a supersatu-
rated solution. Two such solutions were prepared for each solvent, or mixture of 
solvents. The hot solutions were filtered (no. 4 sintered glass filter) and one solution 
of each solvent allowed to self-cool to room temperature, while the other was cooled 
rapidly on ice. Similar recrystallisations were obtained from a mixture of ethyl alcohol 
(95 %), chloroform, n-propyl alcohol and acetone (equal parts), as well as deionised 
water. The recrysta1lised drug was separated by filtration and dried in a dessicator 
(silica gel) for one week before use. Theophylline samples were also mixed with 
sucrose and sodium chloride and recrystallised from ethyl alcohol (95%) to investigate 
the effect of impurities. 
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Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) was performed on 2 - 5 mg quantities of 
each sample of recrystallised theophylline. A Perkin-Elmer DSC-2 Differential 
Scanning Calorimeter and Perkin- Elmer Recorder was used with the adjustments set 
as follows: 
Range: 20/20 
Chart Speed: 10 mm1min 
Heating rate: 200K/min 
Temperature range - Lower limit: 3200K 
- Upper limit: 6200K 
Indium was used as the reference standard. 
Infra-red Spectroscopy 
A Pye Unicam SP3-100 I.R. spectrophotometer was used to produce an IR spectrum 
of each sample using a KBr disc technique. 
Scanning Electron Microscopy 
Scanning electron micrographs of samples were taken using a J eol JSM 840 Scanning 
Electron Microscope at a magnification of 250. Samples were coated with gold prior 
to the microscopic examination using a Polaron E5100 Sputter coater. 
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X-Ray Powder Diffraction 
The X-Ray diffraction patterns of the different samples were measured utilizing a 
Philips PW 1050170 automatic X-ray powder diffractometer fitted with monochroma-
tor and scintillation counter with pulse height selections. 
A PW 2233/20 Cu normal focus tube was run at 50 kV and 30 rnA and was used with 
1° divergence and scatter slits. Diffraction patterns were recorded on a strip chart 
while scanning the sample through a 2() range of 10 - 500. 
2.1.2 Results and Discussion 
Differential Scanning Calorimetry 
There appeared to be no difference in the thermograms of each sample irrespective 
of the solvent or the rate of crystallisation. A typical thermogram (Fig. 2.1a) is that 
obtained for theophylline recrystallised from ethyl alcohol (95%) at a rapid cooling 
rate. An endothermic peak at 538'K (265'C) corresponding to the melting point of 
theophylline anhydrous is seen. 
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Th eophyll ine 
320 400 480 560 640 720 
Temperature/ I::. 
Fig.2.1a DSC thermogram of a sample of theophylline recrystallised from ethyl alcohol (95%) under 
rapid cooling conditions. The endothermic peak at 538'K corresponding to the melting point of 
theophylline anhydrous is shown. 
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Since the thermo grams are similar, the presence of polymorphic forms of theo-
phylline is unlikely under these conditions of recrystallisation. When an impurity such 
as sucrose was present, an additional endothermic peak at about 460"K (186 t:) 
corresponding to sucrose is seen (See Fig. 2.1b). 
Further thermograms were obtained of fused mixtures of theophylline with PEG and 
PVP (Figs. 2.1c, d and e). Endothermic peaks corresponding to the composition of 
the mixtures are seen. Hence there is no evidence of interactions between theo-
phylline and sucrose, PEG or PVP. 
Theophylline + sucrose 
32~0----~--4~0~0--~~--4~OO~---L--~5~60~--~--~M~0----~--~720 
Temperature/K 
Fig.2.1b DSC thermogram of a sample comprising a mixture of theophylline anhydrous and sucrose. 
In addition to the endothermic peak for theophylline at about 4600 K corresponding to sucrose is shown. 
Theophylline + PEG 
320 400 480 560 640 720 
Temperature/K 
Fig. 2.1c DSC thermogram of a fused mixture of theophylline and polyethylene glycol (PEG). In 
addition to the characteristic peak for theophylline, an additional endothermic peak corresponding to 
PEG around 3500 K is seen. 
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Theophylline + PVP 
320 400 560 640 720 
Temperature/ K 
Fig. 2.1d DSC thermogram of a fused mixture of theophylline and polyvinylpyrrolidone (PVP). In 
addition to the characteristic peak for theophylline, an additional broad endothermic peak correspond-
ing to PVP is seen. 
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Temperature/K 
Fig. 2.1e DSC thermogram of a pure sample of PVP. 
Infra-red Spectroscopy 
The infra-red spectra were identical for each sample of recrystallised theophylline. A 
typical spectrum is shown in Fig.2.2 which was obtained from theophylline recrystal-
lised from water at a rapid rate by cooling on ice. The spectrum shows typical principal 
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peaks for theophylline anhydrous atA1660, BlnO and C1440 or 1560. The IR spectra 
demonstrate that no polymorphic changes are evident. 
Fig. 2.2 Infra·red spectrum obtained from a sample of theophylline anhydrous recrystallised from water 
at a rapid cooling rate. The spectrum shows typical principal peaks for theohylline anhydrous at A 1660, 
B1720 and el440 or 1560. 
Scanning Electron Microscopy 
The photomicrographs shown in Fig. 2.3a - i reveal differences in particle shape and 
size due apparently to differences in the polarity of the solvents and the rates of 
cooling. Samples recrystallisd from polar solvents such as water and ethyl alcohol 
produced needle-like crystals with relatively smooth surfaces, whereas more non-
polar solvents such as acetone, chloroform and n-propyl alcohol yielded crystals which 
were plate-like and irregular. The cooling rate appeared to influence the size .of 
crystals produced. A slow cooling rate produced larger crystals while those recrystal-
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lised rapidly on ice resulted in smaller crystals. The effects that polarity and cooling 
rate produce on the shape and size of the crystals formed are illustrated in Fig. 2.4, 
and Table 2.1 is a tabulated summary of these effects. The presence of sucrose and 
sodium chloride as impurities produced imperfections on the crystal surface (See Fig. 
2.3h and i). 
SLOW ~(---- axx.ING RATE ----7) RAPID 
Fig. 2.4 Effect of polarity of solvent and rate of cooling on the size and shape of theophylline particles 
recrystallised from solullons in various solvents. 
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Fig. 2.3 a Scanning electron micrograph of theophylline anhydrous 
particles as received from Holpro Chern. Corp. at a 
magnification X250. The white bars represent 100 pm. 
slow cooling rate rapid cooling rate 
Fig 2.3 b Scanning electron micrographs of theophylline particles 
recrystallised from water at two different cooling 
rates. Magnification X250. White bars represent 100 pm. 
slow cooling rate rapid cooling rate 
Fig. 2.3 c Scanning electron micrographs of theophylline particles 
recrystallised from ethyl alcohol (95%) at two 
different cooling rates. Magnification X250. White 
bars represent 100 pm. 
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slow cooling rate rapid cooling rate 
Fig . 2.3 d Scanning electron micrographs of theophylline particl es 
recrystallised from n-propyl al cohol at two different 
cooling rates. Magnification X250 . White bars 
represent 100 pm. 
slow cooling rate r apid cooling rate 
Fig. 2 .3 e Scanning electron micrographs of theophylline particles 
recrystallised from Acetone at two different cooling 
rates. Magnification X250 . White bars represent 
100 >IDJ . 
slow cooling rate rapid cooling rate 
Fig. 2.3 f Scanning electron micrographs of theophylline particles 
recrystallised from chloroform at two di fferent cooling 
rates. Magnification X250. White bars r epresent 
100 ).lm . 
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slow cooling rate rapid cooling rate 
Fig. 2.3 g Scanning electron micrographs of theophylline particles 
recrystallised from a solvent mixture comprising ethyl 
alcohol (95%), chloroform, n-propyl alcohol and acetone 
in equal parts at two different cooling rates. 
Magnification X250. White bars respresent 100 pm. 
Fig. 2.3 h Scanning electron micrograph of particles of 
theophylline containing sucrose as an impurity 
recrystallised from ethyl alcohol (95%) at a slow 
cooling rate. Imperfections on the crystal surfaces 
are seen. Magnification X250. White bars represent 
100 pm. 
Fig. 2.3 i Scanning electron micrographs of particles of 
theophylline containing sodium chloride as an impurity 
recrystallised from ethyl alcohol (95%) at a slow 
cooling rate. Imperfections on the crystal surfaces 
are seen. Magnification X250. White bars represent 
100 pm. 
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TABLE 2.1 A tabulated summary of the relative shapes and sizes of theophylline crystals recrystallised 
from various solvents at different cooling rates. 
SOLVENT 
WATER 
Rapid cooling 
Slow cooling 
ETIlYL ALCOHOL (95%) 
Rapid cooling 
Slow cooling 
n - PROPYL ALCOHOL 
Rapid cooling 
Slow cooling 
ACETONE 
Rapid cooling 
Slow cooling 
CHLOROFORM 
Rapid cooling 
Slow cooling 
ETIlYL ALCOHOL (95%), 
CHLOROFORM, ACETONE, 
AND n-PROPYL ALCOHOL 
(EQUAL PARTS) 
Rapid cooling 
Slow cooling 
Needles 
Large Small 
(widthflm) 
+(16) 
+(65) 
+(8) 
+ (110) 
+(12) 
+(50) 
SHAPE AND SIZE 
Plates Plates arranged 
in needle form 
Large Small Large Small 
(widthflm) (widthflm) 
+(15) 
+(90) 
+(24) 
+(16) 
+(24) 
+(52) 
Note: The sizes indicated in brackets are an average of 5 readings. Refer to individual scans for actual 
sizes. 
+ = crystal formation 
- = no crystal formation 
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X-Ray Powder Diffraction 
X-Ray powder diffraction studies were carried out on only three samples: 
Sample labelled "T" - Theophylline anhydrous as received from supplier 
(Holpro Chern. Corp) 
Sample labelled "WS" - Theophylline recrystallised from water under slow conditions 
Sample labelled "PRO - Theophylline recrystallised from n-propyl alcohol under 
rapid conditions on ice 
The X-ray powder diffraction data for the above theophylline samples are tabulated 
in Tables 2.2 and 2.3. These data showing peak positions and intensities were obtained 
from diffraction patterns recorded on a strip chart. The data shows that samples 'T' 
and "PR" have identical crystal structures. However the diffraction pattern recorded 
for sample "WS" shows several different features from those obtained for the other 
two samples (See Tables 2.2 and 2.3). These differences occur mainly in the 2£J range 
10 - 24°(Fig. 2.5 and 2.6). Since none of the previous study methods revealed the 
presence of polymorphic changes it was considered possible that the differences 
occuring in Sample "WS" may be a hydrated form of theophylline. The presence of 
trace levels of solvent (in this case water) as a residue from the precipitation process 
may change the physicochemical properties of a substance by becoming a molecular 
addition to the crystal. 
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TABLE 2.2 X-Ray powder diffraction data for theophylline samples "T' and 'PR' 
Sample'T' Sample 'PR" 
da {3 da {3 
6.91 VS 6.% VS 
6.10 M 6.10 VS 
4.92 VW 4.95 VW 
4.23 VW 4.23 VW 
4.07 W 4.09 S 
3.83 M 
3.77 W 3.78 VW 
3.66 M 3.67 S 
3.45 MS 3.46 MS 
3.34 M 3.35 MW 
3.22 M 3.23 M 
3.02 M 3.06 M 
2.92 VW 2.94 VW 
2.87 W 2.88 M 
2.81 VW 
2.74 VW 
2.66 VW 2.66 VW 
2.56 VW 2.56 VW 
2.45 VW 2.45 M 
2.39 VW 
2.34 MW 2.34 M 
2.30 W 2.30 VW 
2.26 VW 
2.12 VW 2.12 VW 
2.07 W 
2.03 VW 2.03 VW 
2.02 VW 1.99 VW 
1.84 VW 1.83 VW 
a"d": interplanar spacing (A) 
{3"I": intensities graded as S (STRONG), M (MEDIUM), W (WEAK) V (VERY) 
34 
TABLE 2.3 X-Ray powder diffraction data for theophylline samples "WS" and ' WS DRIED". 
Sample "WS' 
da t 
Sample "WS DRIED' 
da t 
7.69 S 
7.02 VS 
6.60 S 
6.15 MS 
6.02 VS 
557 VW 
4.98 W 4.95 W 
4.77 M 
4.39 VW 
4.21 W 
4.19 W 
4.07 W 
3.98 W 
3.77 M 
3.67 W 3.66 S 
3.50 VW 
3.46 VS 
3.37 S 3.35 VS 
3.29 VS 3.23 S 
3.21 S 
3.02 MS 3.04 S 
2.89 VW 2.94 VW 
2.86 VW 2.88 W 
2.82 W 
2.75 VW 2.74 VW 
2.66 VW 2.67 W 
2.58 VW 2.56 W 
2.52 VW 
2.48 VW 2.47 W 
2.45 W 
2.34 MW 2.34 S 
2.27 VW 2.30 MW 
2.24 VW 2.24 W 
2.21 VW 2.23 VW 
2.16 VW 2.14 W 
2.12 W 
2.07 MW 
2.03 VW 2.03 MW 
2.01 VW 1.99 W 
a"d": interplanar spacing (A) 
/3"1": intensities graded as S (STRONG), M (MEDIUM), W (WEAK) V (VERY) 
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To investigate this possibility sample "WS" was dried in an oven at lOO"C for 1 hour 
and a sample of this dried material was submitted to X-ray powder diffraction as 
before. Results showed that there was no significant difference in diffraction patterns 
compared to samples 'T' and "PR" (see Table 2.2 and Table 2.3). This evidence 
therefore supports the view that differences in crystal structure between the freshly 
recrystailised sample "WS" and the dried sample is due to pseudopolymorphism 
resulting from the presence of water as a molecular addition to the crystal in the freshly 
re-crystallised material. 
CONCLUSION 
Attempts to recrystallise theophylline from various solvents, both polar and non-
polar, did not produce polymorphic changes to the theophylline crystal, although there 
was evidence of pseudo polymorphism in the sample recrystallised from water. Signi-
ficantly the use of polar and non-polar solvents resulted in differences in the shape 
and size of the crystals as shown in SEM techniques.In the absence of evidence of the 
existenceof any other polymorphic forms under these conditions of recrystallisation, 
it was concluded that further attempts to alter the dissolution characteristics of the 
drug by this means should be discontinued. 
2.2 CRYSTAL SIZE, SHAPE AND DISSOLUTION 
Attempts were then made to investigate the affect of crystal size and shape on the 
dissolution properties of theophylline obtained by recrystallisation from solvents as 
described in Section 2.1.1. In the case of poorly or sparingly soluble drugs, absorption 
is often dissolution rate limited. It is also well known that the size and shape of a drug 
particle has a profound influence upon its dissolution rate consequently affecting its 
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rate of absorption and onset of action (Staniforth, 1988). In certain cases the size of 
the drug particle may be modified in order to obtain the desired physicochemical 
characteristics. It is essential therefore that during early preforrnulation studies the 
particle size and distribution be determined, optimised and controlled when applic-
able. Samples of theophylline used, for dissolution rate determinations were: 
1. Crystals as received from Holpro Chemical Corporation. 
Short, rod-like particles variable in size from about 100 - 500}lm long and 50 - 100 
}lm wide. 
2. Crystals recrystallised from water under slow cooling conditions. 
Long, needle-like crystals averaging about 1000}lm in length and about 100}lm 
in width. 
3. Crystals recrystallised from n-propyl alcohol by cooling rapidly on ice. 
Thin, plate-like fragments of irregular shape ranging in length from less than 10 
}lm to about 80 - 100 }lm. 
2.2.1 Sieve Analysis 
There are a number of methods of particle size analysis of a powder. One of the most 
commonly used methods is employing a variety of sieves. The sieve analysis is usually 
carried out using dry powders with metal sieves of known aperture diameters. Aseries 
or a nest of sieves which have the smallest mesh above a collector tray followed by 
meshes which get progressively coarser towards the top of the series. In this analysis 
four stainless steel sieves of mesh sizes 390 }lm, 250}lm, 190}lm and 75 }lm, and a 
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Erweka AR 400 mechanical shaker was used. Samples of known mass of each of the 
above three types of crystal were subjected to sieve analysis to determine the size 
distribution of each. About 5g of sample, accurately weighed, was loaded on to the 
top coarsest sieve of the assembled stack and the nest was subjected to mechanical 
vibration for 10 minutes. The particles are considered to be retained on the sieve 
mesh with an aperture corresponding to the minimum or sieve diameter. For a 
comparison to be made of the characteristics of the powders, the size distribution can 
be broken down into different size ranges which can be presented in the form of a 
histogram. Such a histogram enables the percentage of particles having a given 
equivalent diameter to be determined and allows different particle size distributions 
to be compared. 
Results of Sieve Analysis 
A histogram of each sample indicating the percentage of powder lying between 
different mesh sizes is shown (Fig. 2.7 to 2.9). The size distribution of the drug sample 
recrystallised from water as well as the sample recrystallised from n-propyl alcohol 
contain a larger proportion of large particles than the powdered theophylline as 
received from Holpro in which the particles are almost normally distributed. Both 
recrystallised samples exhibit skewness of the frequency distributions. Both fre-
quency curves have an elongated tail toward the smaller size ranges and are therefore 
negatively skewed. 
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Fig. 2.7 Histogram of sample 1 indicating the percentage of powder lying between different mesh sizes. 
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Fig. 2.8 Histogram of sample 2 indicating the percentage of powder lying between different mesh sizes. 
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Fig. 2.9 Histogram of sample 3 indicating the percentage of powder lying between different mesh sizes. 
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2.2.2 EFFEcr OF PARTICLE SIZE ON DISSOLUTION RATE 
In instances where the bioavailability of a drug is dissolution rate limited, absorption 
into the system may be increased by a reduction in drug particle size and hence an 
increase in total surface area. For sustained release dosage forms of the' drug, it may 
be possible to reduce absorption by increasing the particle size. This is clear from the 
Noyes-Whitney equation 
dm 
dt 
DA 
h 
(Cs - C) 
where dm/dt is the rate of dissolution, D is the diffusion coefficient, A is the effective 
surface area of the drug particles, h is the diffusion layer thickness, Cs is the saturation 
solubility of the drug in the diffusion layer and C is the concentration of drug in 
solution .. The following study was performed to determine the effect of particle size 
on the dissolution rate of the three recrystallised theophylline samples subjected to 
sieve analysis. 
Method 
A beaker containing 200 rnL of distilled water was placed on a magnetic stirrer with 
the stirring rate adjusted to 32 rpm.The distilled water was used as received from the 
reservoir of the still at a temperature of 19°C. Exactly 0.5 g of the first sample was then 
quickly added all at one time to the water. A stop watch was started immediately the 
solid entered the water. At exactly one minute, 1 rnL of the solution was removed and 
passed through a 0.45 "m membrane filter (Millipore) to remove undissolved solids 
from the solution. An equivalent volume of distilled water at 19°C was added to 
maintain constant volume. The 1 rnL sample was diluted to 100 rnL with water and 
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the theophylline concentration determined by UV spectrophotometry at 271 nm. The 
above sampling procedure was repeated at 2, 4, 6, 8 and 10 minutes. The dissolved 
theophylline (mg) was plotted against time (minutes). The above method was re-
peated with 0.5 g quantities of samples 2 and 3. 
Results and Discussion 
The dissolution profiles of each sample are shown in Fig. 2.10. The dissolution profiles 
show thatthe plate-like particles (sample 3) have a faster rate of dissolution than those 
particles received from the supplier (Holpro) (Sample 1). The latter in tum have a 
faster dissolution rate than the long needle-like particles (Sample 2). The differences 
in the rates of dissolution can be explained in terms of the differences in surface area 
of the particles. The large needle-like crystals having the smallest surface area will 
produce the slowest dissolution rate, whereas the plate-like particles although inter-
mediate in size have the largest surface area and hence a faster dissolution rate. The 
smallest particles (sample 1) are rod-like. Because of their shape the surface area of 
the short rods is smaller than the plates. 
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Fig. 2.10 The effect of particle size and shape on the dissolution rate of theophylline in distilled water 
at 19°C. 
oj- ,drug particles recrystallised from n-propyl alcohol 
'* , drug particles as received from supplier (Holpro Chem. Corp.) 
o , drug particles recrystallised from water. 
Conclusion 
The graph (Fig.2.1O) shows significant differences in dissolution rate of the drug 
particles over a relatively short time period of 10 minutes. However when formulating 
sustained release dosage forms designed to release the drug constantly over 12 hour 
time periods, these differences might therefore be considered insignificant. 
23. pH SOLUBILITY PROFILE 
A drug must possess some aqueous solubility, irrespective of the route of administra-
tion, in order to be physiologically active. Aqueous solubility is however not the only 
factor influencing absorption. Other factors such as degree of ionisation and lipid 
solubility can also be important. 
The aqueous solubility of many drugs will vary according to the pH of its environment. 
It is clear therefore that the solubility of a drug may vary at different positions along 
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the gastro- intestinal tract. The gastric juice has a pH of 1 - 3 with the pH increasing 
gradually toward the distal regions of the intestine where the pH could be as high as 
8. A study was performed to determine the pH solubility profile for theophylline 
anhydrous. 
Method 
The method employed was based on equilibrium solubility. An excess of theophylline 
anhydrous (5 g) was added to 200 mL of 0.05 M phosphate buffer at pH 1.5 in a beaker. 
The suspension at 37°C was stirred on a magnetic stirrer until eqUilibrium was 
achieved (about 24 hours). At equilibrium 5 mL of suspension was withdrawn and 
quickly filtered through a 0.45 /lm membrane filter. The 5 mL of filtered solution was 
diluted to 200 mL with water. A 5 mL volume of this diluted solution was then further 
diluted to 250 mL. The absorbance of this solution was measured at 271 nm and the 
concentration of theophylline calculated. Appropriate quantities of 0.1 M NaOH was 
added to the suspension to raise the pH to suitable higher levels. After equilibrium 
was reached each time (24 hours) the above sampling and diluting procedure was 
repeated and the diluted solution assayed for theophylline. 
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Results and Discussion . 
The pH solubility profile for theophylline is illustrated in Fig. 2.11. 
Equilibrium Concentration (mg/mL) 
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Fig. 2.11 Curve showing the pH solubility profile of theophylline anhydrous B.P. in phosphate buffer. 
These results show that there is little change in equilibrium solubility over the pH 
range about 2 - 7. There is however a significant increase in solubility at pH values 
above 7.4. The greater solubility of theophylline at pH values above 7.4 would 
probably indicate that theophylline would have a greater solubility in the alkaline 
intestinal fluid. Thus the drug would be more rapidly absorbed in this region of the 
GIT since the drug is non-ionising and has a pKa value of 8.3 at 37°C (Zuidema J., 
1983). 
2.4 INTRINSIC DISSOLUTION 
It is a well established fact that an orally administered drug must first dissolve in the 
gastrointestinal fluids for absorption to take place. The dissolution rate data as well 
as the information on the solubility, pKa and partition coefficient of the drug will 
provide useful insight into its potential in vivo absorption characteristics. The dissol-
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ution rates of theophylline from different crystal forms and particle sizes have already 
been demonstrated under a previous section entitled "Crystal Size, Shape and Dissol-
uti on". The intention of this study was to determine the intrinsic dissolution rate of 
theophylline by the constant surface method under sink conditions. Moreover solid 
dispersions of theophylline with certain polymeric substances were prepared and the 
intrinsic dissolution rate similarly determined. 
2.4.1 Measurement of the Intrinsic Dissolution Rate of Theophylline Anhydrous 
Materials and Method 
A compression die similar to Wood's Apparatus (Wood et al., 1965) was designed 
(Fig. 2.12). A disc (11 mm diameter) of pure anhydrous theophylline powder (Holpro) 
was prepared by slow compression using and Instron machine. A high compaction 
pressure to ensure zero porosity was employed together with a long dwell time. 
Employing the USP XXI paddle method of dissolution, the intrinsic dissolution rate 
of theophylline was determined using 1 L of distilled water as dissolution medium. 
The brass holder containing the disc was positioned as shown in Fig. 2.12. The 
temperature of the water was 37±0.5'C and the paddle was rotated at 50 rpm. The 
amount of drug released was monitored with time by U.V. spectrometry at 271 nm 
and removing samples of dissolution medium at 5 minute intervals during the first 
hour of release. Sink conditions were prevailing throughout the dissolution measure-
ments. An equivalent volume of water at 37' C was added to maintain constant 
volume. The above determinations were carried out in quadruplicate and the mean 
theophylline concentrations (mgIL) were plotted against time (minutes). 
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Fig. 2.12 Diagram showing the apparatus used to determine intrinsic dissolution of theophylline. The 
compressed disc is shown fitting into the brass holder. The perspex paddle is driven at 50 rpm by a 
variable speed motor. 
Results and Discussion 
The plot of theophylline concentration against time was linear (Fig. 2.13) indicating 
that sink conditions were maintained. 
The slope of the line divided by the exposed surface area gives the intrinsic 
dissolution rate expressed in mglcm2.min. 
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Fig.2.13 Plot illustrating the intrinsic dissolution profile of theophylline in water by the constant surface 
method. 
The surface area of the exposed disc surface was 0.951 cm2. The intrinsic dissolution 
rate K was calculated using the equation: 
K = W/tA where W is the quantity of drug 
dissolved in time t 
and A is the surface area of the disc surface. 
The calculated intrinsic dissolution rate for theophylline under the above conditions 
was 2.54 mglcm2.min. However, it should be noted that there are a number of factors 
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which significantly influence the calculated intrinsic dissolution rate of a substance. 
These include the agitation rate and the position of the disc holder. It is absolutely 
essential therefore when making comparisons of intrinsic dissolution rates to ensure 
that dissolution conditions are exactly similar. 
It was noted that during the dissolution process more erosion occurred along the disc 
surface nearer to the side of the flask. (Fig. 2.14) . 
.-
~-
/ / 
/ 
Fig. 2.14 Diagram illustrating the greater erosion rate occurring on the disc surface nearer to the side 
of the dissolution flask. 
This phenomenon can be attributed to the fact that the moving pattern of the 
dissolution medium becomes progressively faster from the centre where the paddle 
shaft joins the paddle towards the sides of the flask where the moving pattern is at its 
highest speed. This would increase the dissolution rate of the drug along the outer 
surface. Therefore the exact position of the solid surface in relation to the paddle is 
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an important factor influencing the intrinsic dissolution rate. Since the rate of 
dissolution is not constant over the entire disc surface area, it would seem that 
eccentrically mounted discs as proposed by Nicklasson and Magnusson, (1985) would 
result in a more constant fluid flow over the disc surface. Rotating disc methodology 
was also employed by Dubois and F<;>rd, (1985) when examining the dissolution rates 
of 10 drugs which were solid dispersed by fusion in polyethylene glycol 6000. 
2.4.2 Measurement of the Intrinsic Dissolution Rate of Theophylline from Solid 
Dispersions. 
A solid dispersion has been defined by Chiou and Riegelman, (1971) as "dispersion 
of one or more active ingredients in an inert carrier or matrix at solid state prepared 
by the melting (fusion), solvent, or melting-solvent method." The concept of solid 
dispersions was introduced in order to increase the bioavailability of many poorly 
water-soluble drugs which are dissolution rate limited. However research conducted 
in the area of solid dispersions encompasses both fast release as well as sustained 
release products. Work done by Simonelli et al., (1969) has shown that large increases 
in the dissolution rates of drugs from solid dispersions have occurred. The mechan-
isms involved in the increased dissolution rates are discussed by Ford, (1986) in his 
review article on the current status of solid dispersions. The drug must be transferred 
to a higher energy form to produce more rapid dissolution and this is most easily 
accomplished at high carrier levels when the carrier dissolves rapidly bringing the 
dispersed drug into solution. Examples of such carriers include polyethylene glycols 
and polyvinyl- pyrrolidones. It follows that the presence of insoluble polymers such 
as ethylcellulose and Eudragit@wouldproportionatelyreduce the dissolution rate of 
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the drug from a solid dispersion where soluble carriers were also present. Solid 
dispersions of drugs in carriers of low solubility offer the potential for sustained 
release. This work was carried out to demonstrate the affect· of both soluble and 
insoluble polymers on the dissolution rate of theophylline from solid dispersion. A 
knowledge of the dissolution behaviour could be applied in the design of sustained 
release dosage forms. 
Materials and Method 
The constant surface method eliminates changes in surface area and surface electrical 
charge as dissolution variables. Solid dispersions of theophylline with various poly-
mers were prepared by the fusion method. The composition of each of the two solid 
dispersion formulations are given below. 
Formulation 1 
Theophylline anhydrous 2.0 g 
Polyvinylpyrrolidone 2.0 g 
Polyethylene glycol 1540 7.0 g 
Formulation 2 
Theophylline anhydrous 2.0 g 
Ethylcellulose 2.0 g 
Polyethylene glycol 6000 7.0 g 
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The solid dispersions were made by slowly melting the polyethylene glycols on a hot 
plate at a low temperature and then stirring in the other two components to produce 
a smooth suspension in the molten mixture. The molten mixtures were then poured 
carefully into the same brass holders used for the measurement of the intrinsic 
dissolution rate of theophylline anhydrous described previously. After solidifying the 
surplus dispersion was gently scraped away to yield a surface completely flush with 
the brass holder. Employing the USP XXI paddle method as before, the intrinsic 
dissolution rate of theophylline from each solid dispersion formulation was deter-
mined in triplicate. Distilled water (IL) at 37±0.5°C was used as dissolution medium. 
The paddle was rotated at 50 rpm during each determination except for one determi-
nation using formulation 2 where the paddle speed was 100 rpm. The sampling of 
dissolution medium and the assay for theophylline was performed as described 
previously. The mean percent of theophylline dissolved was plotted against time 
(minutes). 
Results and Discussion 
The plots of percentage drug dissolved against time are shown in Fig. 2.15. Because 
of the water solubility of the polymers polyvinylpyrrolidone and polyethylene glycol 
in Formulation 1, the theophylline present in this formulation dissolves more rapidly 
in comparison to Formulation 2 containing the insoluble polymer ethylceUulose which 
tends to impede the dissolution process significantly. However, increasing the rota-
tional speed of the paddle to 100 rpm increases the dissolution rate of theophylline 
from Formulation 2. Fig. 2.15 also shows the dissolution profile of pure theophylline 
anhydrous. It can be clearly seen that the presence of theophylline in the form of a 
solid dispersion with various polymers resulted in a great increase in the rate of 
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dissolution which depended upon the composition of the fused solid dispersion as 
well as the agitation speed. 
The intrinsic dissolution rates of theophylline from the two solid dispersion formula-
tions were calculated and compared. 
Formulation 1 Intrinsic dissolutio~ rate (50 rpm) 4.2 mg/cm 2min 
Formulation 2 Intrinsic dissolution rate (50 rpm) 1.9 mg/cm 2min 
Formulation 2 Intrinsic dissolution rate (100 rpm) 3.2 mg/cm 2min 
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Fig 2.15 Dissolution profiles showing the % of theophylline released against time (minutes) from discs 
by the constant surface method. 
H< Theophylline in solid dispersion with PVP and PEG 154() (50 rpm) 
C Theophylline in solid dispersion with ethylcellulose and PEG 6000 (100 rpm) 
X Theophylline in solid dispersion with ethylcellulose and PEG 6000 (50 rpm) 
¢ Theophylline Anhydrous (pure) (50 rpm) 
Conclusion 
The presence of a soluble polymer, such as PEG and PVP, significantly increased 
the dissolution rate of theophylline from solid dispersion. The incorporation of an 
insoluble polymer, ethylcellulose, however significantly decreased the dissolution rate 
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and demonstrates that ethylcellulose will be useful in impeding the drug dissolution 
rate in sustained release formulations. It is also noteworthy that the dissolution rate 
depends largely on the speed of agitation. Ethylcellulose and PEG were used because 
they are commonly used non-toxic polymers in sustained release technology and will 
feature prominently in certain parts .of the work that follows. 
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CHAPTER THREE 
GRANULATION, FILM COATING OF GRANULES AND ASSESSMENT OF 
DRUG RELEASE FROM GRANULES 
Fluidised bed film coating technology was used to film coat granules of theophylline 
with polymeric materials. These granules contained a high proportion ofihe drug and 
were sufficiently hard to prevent fracture or powdering during the film coating process 
when the granules are in constant rapid motion. Work was carried out therefore to 
determine which of the binders in general pharmaceutical use would produce gra-
nules possessing sufficient hardness. 
3.1 GRANULE PRODUCTION 
3.1.1 Materials and Methods 
The binding materials investigated were acacia, gelatin and maize starch, each of 
which were according to B.P. 1980 specifications. Other binders used were sodium 
carboxymethylcellulose (Holpro), sucrose (BDH) and polyvinylpyrrolidone 40 000 
(Sigma). 
A sufficient quantity of an aqueous solution of each binder was added to 50 g 
theophylline anhydrous in fine powder while mixing to produce a wet mass. The 
concentrations and volumes of the aqueous solutions of the binders used are provided 
in Table 3.1. Acacia and gelatin were each used at two different concentrations. The 
soft masses were passed through a sieve (2 mrn) and dried at 55°C for 8 hours. After 
drying the coarse granules were passed through a sieve (2 rnrn with 1.25 rnrn under-
neath). The granules produced were in the range < 2 rnrn > 1.25 rnrn. The approxi-
mate concentration (% w/w) of each binder in the dried granulated material is shown 
in Table 3.2. 
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Table 3.1 Concentrations and volumes of binder solutions required to mix with 50 g of anhydrous 
theophylline to produce a suitable wet mass 
Binder and concentration 
of solution (% w/v) 
Acacia 20% 
Gelatin 20% (> 45°C) 
Sucrose 60% 
Sodium carboxymethylcellulose 5% paste 
Polyvinylpyrrolidone 15% 
Starch paste 10% 
Acacia 40% 
Gelatin 40% (> 45°C) 
3.1.2 Hardness Testing 
Volume or weight of solution 
required (mL or g) 
12,SmL 
12.5 mL 
13.5 mL 
15.0 g 
12.5 mL 
15.0 g 
15.0mL 
15.0mL 
A comparison of the hardness of the various granules was made utilising a Erweka 
TBH 28 Tablet Hardness Tester. Since the granules were less than 2 mm in diameter, 
a stainless steel strip 5 mm thick was used to line the pressure plate making it possible 
for the granule to be crushed before the plate returned to its resting position. 
Ten granules of each sample were tested and the pressure (Newtons) required to 
fracture each granule was recorded. The mean pressure for each sample is shown in 
Table 3.2 in order of decreasing hardness. 
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TABLE 3.2 
Binder 
(%w/w in dried granules) 
Gelatin 10.7% 
Sodium carboxymethylcellulose 1.5% 
Gelatin 4.7% 
Acacia 10.7% 
Starch 2.9% 
Acacia 4.7% 
PVP3.6% 
Sucrose 13.8% 
Mean pressure (Newtons) 
±S.D. 
30.2 ±6.3 
20.8 ±7.0 
163 ±4.2 
15.9 ±3.9 
12.0 ±2.7 
11.0 ±3.8 
7.8 ±1.8 
7.2 ±1.8 
Although gelatin 10.7% produced the hardest granule (30.2N), a limitation to its use 
was its relatively high viscosity and concentration. The aim was to produce a granule 
sufficiently hard yet retaining as high a theophylline content as possible. The hardness 
value for sodium carboxymethylcellulose was significantly lower (20.8N) yet the 
granules were sufficiently hard for fluidised bed techniques and with a much lower 
concentration of binder (1.5%). Therefore granules of theophylline prepar.ed using 
sodium carboxymethylcellulose were considered the most suitable. These granules 
had a theophylline content of not less than 98% w/w. 
3.2 FILM COATING PROCESS 
Using sodium carboxyrnethylcellulose as binder, granules of theophylline in the size 
range of < 1.25 mm> 0.8 mm were produced. The granules in this size range were 
suitable for coating and encapsulation, although for practical reasons it was only 
57 
possible to test for hardness the granules in the size range 1.25 - 2.0 mm. Batches of 
granules were film coated with ethylcellulose and polyethylene glycol (PEG) under 
the optimally controlled coating conditions shown in Table 3.3, 
The composition, concentration and volume of polymer solution delivered was ad-
justed so as to produce three batclies of granules differing in the composition and 
amount of coating (expressed as % w/w) as follows: 
1. Ethylcellulose 5% 
2. Ethylcellulose 5% + PEG 15402% 
3. Ethylcellulose 5% + PEG 15405% 
The ethylcellulose 10 cps used was obtained from Hercules Inc., Wilmington and the 
PEG 1540 from Riedel-De Haen AG, Seelze- Hannover. 
TABLE 3.3 Conditions under which the granules were fUm coated by fluidised bed technology (upward 
spray method) 
Granule bed weight 
Coating solution 
Solution delivery rate 
Atomising air pressure 
Rated value drying temperature 
Drying temperature 
Outlet air temperature 
FJuidising air flow rate 
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50 g 
5 - 10% w/v of total polymer in isopro-
panol:acetone 1: 1 
8-10mUmin 
2 1.8 -2.0 kg/em 
45'C 
SO'C 
4O' C 
80 - 100 m3/h 
The solvents isopropanol and acetone were of analytical reagent grade. An Aero-
matic AG Film Coating Dryer was utilised for the fluidised bed coating process 
(Muttenz, Switzerland). 
3.3 In Vitro DRUG DISSOLUTION STUDIES 
3.3.1 Method 
The modified USP XXI paddle method was utilised for the in vitro dissolution studies 
of theophylline from 0.5 g samples of coated granules contained in the stainless steel 
meshed basket. The apparatus used was a Hanson Dissolution Drive Control and 
Multiple Spindle Drive (Northridge Ca.) with a constant temperature water bath at 
37±0.saC. The dissolution medium consisted of 1 L of dilute hydrochloric acid pH 
1.2, deionised water and phosphate buffers of pH 2.6 - 5.4. The paddles were rotated 
at a speed of 50 ± 1 rpm. Suitable volumes of dissolution medium were removed at 
30 minute time intervals, diluted appropriately with the dissolution medium and the 
absorbance measured at 271 nm using a Beckman Model 25 spectrophotometer. An 
equal volume of dissolution medium was added at 37°C in order to maintain constant 
volume in each case. Exhausted granules remaining in the baskets after dissolution 
were dried carefully on filter paper and examined by scanning electron microscopy 
using a JEOL ISM 840 scanning electron microscope. Samples were quench-frozen 
in sub-cooled nitrogen ( < -20o-C), freeze-fractured, sputter- coated with gold making 
use of a HEXLAND CT 1000 cold stage and cryo preparation accessory. 
3.3.2 Results and Discussion 
Dissolution profiles showing the concentration of theophylline (mgfL) against time 
(minutes) are shown in Fig. 3.1. Consistent with the findings of other workers 
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Fig 3.1 In vitro dissolution profile of theophylline from granules wated with ethyl cellulose and PEG 
1540 in dilute hydrochloric acid pH 1.2 
+ Ethykellulose 5% w/w 
• Ethylcellulose 5% + PEG 1540 2% w/w 
o Ethylcellulose 5% + PEG 1540 5% w/w 
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c 
60 
B 
Fig 3.2 Scanning electron micrographs of the 
insoluble ethylcellulose coatings remaining after 
dissolution testing from theophylline granules 
coated with: 
A Ethylcellulose 5% 
B Ethylcellulose 5% + PEG 1540 2% 
C Ethylcellulose 5% + PEG 1540 5% 
(Lippold and Forster., 1982; Donbrow and Friedman., 1975; Samuelov et al., 1979) it 
can be seen that the presence of PEG in ethy1cellulose filrns significantly increases 
the rate of drug release through the polymeric membrane compared with that when 
PEG is absent. Morever an increase in PEG concentration will directly increase the 
rate of release. The water-soluble ~EG is rapidly leached out of the coating film 
producing pores or channels through which the dissolved theophylline may pass. The 
presence of pores is confirmed on inspection of the SEM's of the exhausted granules 
(See Fig. 3.2). The mechanism by which the drug molecules pass through the ethy1cel-
lulose membrane coating is by diffusion and this would account for the much slower 
release rate from granules coated with ethy1cellulose only. 
3.4 CAST POLYMER FILMS 
To demonstrate the geometry and nature of pores formed in films consisting of a 
mixture of ethy1cellulose (insoluble polymer) and PEG 1540 (soluble channelizing 
agent) after exposure to various dissolution media, films were prepared, immersed in 
dissolution medium, dried and examined by scanning electron microscopy. The effect 
of a soluble liquid channelising agent such as polysorbate 20 was also investigated. 
3.4.1 Preparation 
Utilising a mixture of equal parts of acetone and isopropanol as solvents, solutions 
containing a mixture of ethy1cellulose and PEG 1540 or polysorbate 20 at different 
concentrations were prepared. Table 3.4 shows the concentrations of ethy1cellulose, 
PEG 1540 and polysorbate 20 in the solvent mixture. 
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TABLE 3.4 
The concentrations of ethylcellulose, PEG 1540 and polysorbate 20 in the solvent mixture (% w/v) 
Ethylcellulose PEG 1540 Polysorbate 20 
A 3 2 
B 5 2 
C 10 2 
D 3 5 
E 5 5 
F 10 5 
G 3 10 
H 5 10 
I 10 10 
J 5 
K 5 5 
Using a pipette 1 mL of each solution was placed into the centre of glass rings (30 rnm 
in diameter) resting horizontally and evenly on a smooth clean glass surface. Evap-
oration of the solvents took place overnight (18 hours) at room temperature (16 -
19°C). The dried cast films were then carefully removed from the glass surface and 
two small strips measuring about 12rnm x 4rnm were cut from near the centre of each 
film. Specially designed plastic clips were used as film holders for dissolution studies. 
3.4.2 Dissolution 
The dissolution apparatus with paddle was used. One dissolution beaker contained 1 
L of deionised water (PH 6.8) while the other contained 1 L of 0.1 M phosphate buffer 
at pH 2.3. One strip from each film was immersed in the water while the other in the 
phosphate buffer. The dissolution media were maintained at 37°C and the paddles 
rotated at'SO rpm to maintain circulation for 1 hour. As a control a film prepared from 
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a solution of ethylcellulose (no channelising agent) was cut similarly into strips and 
immersed in the dissolution media. The strips were then air-dried on filter paper and 
examined by scanning electron microscopy. The SEM photomicrographs are shown 
in Fig.3.3. 
3.4.3 Results and Discussion 
The immersion of the strips in aqueous fluid caused the soluble channelising agents, 
PEG 1540 and polysorbate 20, to dissolve producing pores or channels in the insoluble 
ethylcellulose film. In general the numerical distribution of these pores was directly 
proportional to the PEG concentration. An unexpected result was the tendency for 
thicker films to yield smaller diameter pores in comparison to the thinner films 
yielding larger pore diameters. 
The explanation for this unexpected result is probably that the arbitrarily chosen 
immersion time of one hour was possibly insufficient for moisture to penetrate the 
thicker films and dissolve the soluble constituents completely (See Fig. 3.3 C and F 
which show indentations or craters on the film surface). The average approximate 
pore diameters and thicknesses of the films are shown in Table 3.5. In the case of the 
film containing polysorbate 20, a liquid channelising agent, the SEM at higher 
magnification (XSOOO) (Fig. 3.3 K) shows pores which are much more numerous but 
also very much smaller in diameter (0.1 - 0.4 I'm) than the comparable film (Fig. 3.3 
E) comprising ethylcellulose and PEG 1540. The film without channelising agent 
(Fig. 3.3 J) produced no pores at the same magnification (X3000). The pH of the 
dissolution medium does not appear to produce any significant difference on the size 
or numerical distribution of the pores. Therefore it appears that the solubility of the 
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channelising agents used was not affected by the differences in the pH and composi-
tion of the medium. 
TABLE 3.5 
The average pore diameters (±S.D.) and th~ thicknesses of the polymer films cast from various solutions 
of ethylcellulose and PEG 1540 after immersion in dissolution medium 
Ethylcellulose concentration (% w/v) 
Pore diameter (pm) 
Film thickness (pm) 
3 
4.8±3.1 
60 
5 
2±O.8 
85 
10 
O.9±O.7 
145 
NOTE: Concentrations of 2%, 5% and 10% PEG 1540 were used in these films. 
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Fig. 3.3A SEM's of cast 
polymer films produced from a 
solution of ethylcellulose 3% 
and PEG 1540 ~f, in isopropanol: 
acetone 1:1 
1 After dissolution in water 
(pH 6 .8) - surface view 
2 After dissolution in buffer 
solution (pH 2.3) - surface 
view 
3 Cross section through film 
2 
Fig. 3.3B SEM 's of cast 
polymer films produced from a 
solution of ethylcellulose 5% 
and PEG 1540 ~f, in isopropanol: 
acetone 1: 1 
After dissolution in water 
(pH 6 .8) - surface view 
2 After dissolution in buffer 
solution (pH 2 .3) - surface 
view 
3 Cross section through f ilm 
1 
3 
1 
3 
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Fig . 3.3C SEM's of cast 
polymer films produced from a 
solution of ethyl cellulose 1ry/o 
and PEG 1540 ~/o in isopropanol: 
acetone 1:1 
After dissolution in water 
(pH 6.8) - surface view 
2 After dissol ution in buffer 
solution (pH 2 .3) - surface 
view 
3 Cross section through film 
2 
Fig. 3.3D SEM's of cast 
polymer films produced from a 
solution of ethyl cellulose 3% 
and PEG 1540 5% in isopropanol: 
acetone 1:1 
1 After dissolution in water 
(pH 6.8) - surface view 
2 After dissolution in buffer 
solution (pH 2.3) - surface 
view 
3 Cross section through film 
1 
3 
1 
3 
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2 
Fig . 3.3E SEM ' s of cast 
polymer films produced from a 
solution of ethylcellulose 5% 
and PEG 1540 5% in isopropanol : 
acetone 1:1 
After di ssolution in water 
(pH 6 .8) - surface vi ew 
2 After dissolut ion i n buffer 
solution (pH 2 .3) - sur face 
view 
3 Cross section through film 
2 
Fig. 3.3F SEM ' s of cast 
polymer fi l ms produced from a 
solution of ethylcellulose 1 ~~ 
and PEG 1540 5% in isopropanol : 
acetone 1:1 
After dissolution in water 
(pH 6 .8) - sur face vi ew 
2 After dissolution i n buf fer 
solution (pH 2 .3) - surface 
view 
3 Cr oss section through film 
3 
3 
2 
fig. 3.3G SEM's of cast 
polymer films produced from a 
solution of ethylcellulose ~/o 
and PEG 1540 1 ~/o in isopropanol: 
acetone 1:1 
After dissolution in water 
(pH 6.8) - surface view 
2 After dissolution in buffer 
solution (pH 2.3) - surface 
view 
3 Cross section through film 
2 
fig. 3.3H SEM's of cast 
polymer films produced from a 
solution of ethylcellulose 5% 
and PEG 1540 10% in isopropanol: 
acetone 1:1 
After dissolution in water 
(pH 6.8) - surface view 
2 After dissolution in buffer 
solution (pH 2.3) - surface 
view 
3 Cross section through film 
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Fig. 3.3J SEM of a cast 
polymer film produced from a 
solution of ethyl cellulose 5% 
in isopropanol:acetone 1:1 
(No PEG 1540 included) 
Surface view after dissolution 
in water 
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2 
Fig. 3.31 SEM's of cast 
polymer films produced from a 
solution of ethylcellulose 1~~ 
and PEG 1540 10% in isopropanol: 
acetone 1:1 
1 After dissolution in water 
(pH 6.8) - surface view 
2 After dissolution in buffer 
solution (pH 2.3) - surface 
view 
3 Cross section through film 
Fig. 3.3K SEM of a cast 
polymer film produced from a 
solution of ethylcellulose 5% 
and polysorbate 20 5% in 
isopropanol: acetone 1:1 
Surface view after dissolution 
in water 
3.5 INFLUENCE OF POLYMER COATING, DISSOLUTION MEDIUM AND pH 
VARIATION ON THEOPHYLLINE RELEASE FROM ENCAPSULATED GRA-
NULES 
In recent years a number of solid orally administered dosage forms have been 
produced in the form of coated granules or pellets that can be enclosed in hard 
gelatin capsules (Lippold and Forster, 1982; Alkan et al., 1988; Kawashima et al., 
1985; Motycka et al., 1985; Herman et al., 1988; Kohri et aI., 1989; Suryakusuma and 
Jun, 1984; Mehta and Jones, 1985; Beckett et al., 1989). Coated granules or pellets 
possess distinct advantages over conventional dosage forms in that the release char-
acteristics can be more precisely controlled and hence utilised in the design of 
modified release drug delivery systems. To achieve these ends the coating process 
and the evaluation of the coating is critical. The following study investigates the 
production of film coated granules by the direct application of ethylcellulose coatings 
(multilayered) to hard granules of theophylline. Ethylcellulose is a typical example 
of a polymer used for such a purpose as it remains intact throughout its passage 
through the GIT but permits the diffusion of digestive fluid. This infused fluid 
dissolves the drug material and then diffuses out again. The air suspension coating 
process has been utilised because the method is flexible, versatile and the variables 
can be easily controlled. 
3.5.1 Experimental 
Theophylline granules (1.6 ± 0.4 mm in diameter) with sufficient hardness (average 
20 N) were prepared in the same manner as described in the previous section using 
sodium carboxymethylcellulose as binder (theophylline content not less than 98% 
w/w). Batches of granules were film coated (fluidised bed technology) under opti-
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mally controlled conditions to maintain reproducibility (see Table 3.3 for coating 
conditions). 
The process involved spray coating of the granules with a 5 % w/v solution of ethylcel-
lulose in equal parts of isopropanol/acetone providing final amounts of ethylcellulose 
coating of 5%,10%, 12.5% and 15% w/w on the granules. Adequate drying times (15 
minutes at 50"C) were allowed between successive coatings in order to achieve the 
final levels of coatings. 
The theophylline content in each batch was determined by the method of the BP 1980 
(Vol 11) under the monograph of Aminophylline tablets. 
In vitro drug dissolution tests on 300 mg of encapsulated samples (size 0 hard gelatin 
capsules) were carried out using the USP XXI paddle method. The paddle speed was 
50 rpm and the dissolution medium was in most instances 1 L distilled water at 37°C. 
Phosphate buffer (0.1 M) at three different pH's (7.5, 5.0 and 2.5) as well as acidified 
water (dilute Hel) at pH 5.0 and pH 2.4 were also used as dissolution media. As a 
control the dissolution rate of uncoated granules was also monitored. At suitable time 
intervals the dissolution medium was sampled, diluted appropriately and the UV 
absorbance measured at 271 nm. Equivalent volumes of dissolution medium were 
added to maintain constant volume. The experiments were carried out under ident-
ical hydrodynamic conditions. 
Scanning electron micrographs of coated granules, both before and after dissolution, 
were made using a JOEL JSM 840 scanning electron microscope. Samples were 
quench-frozen in sub-cooled nitrogen « -20o-C), freeze-fractured, sputter- coated 
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with gold making use of a HEXlAND cr 1000 cold stage and cryo preparation 
accessory. 
3.5.2 Results and Discussion 
The percentage of theophylline dissplved against time in hours and the release rate 
(mglhour) are represented in Figs. 3.4 and 3.5 respectively which shows the values for 
granules coated with an amount of 5%, 10%,12.5% and 15% w/w of ethylcellulose. 
These values each represent the means of three determinations. Pseudo- steady state 
release of theophylline was obtained from granules coated with 15% w/w of ethylcel-
lulose over a period of 12 hours (See Fig. 3.6). However, there was an initial lag time 
of 1 - 2 hours before any drug was released. This lag time was the time required for 
the aqueous medium to diffuse through the membrane, dissolve the drug and pass 
back through the membrane by diffusion. Moreover the maximum percentage of drug 
released over the 12 hour period for granules coated with 15% polymer was slightly 
less than 50%. Even after a 24 hour period only 65% of the drug was dissolved (Fig. 
3.7). Despite these limitations the in vitro release rate from these 15% coated granules 
was constant over the time period 3 - 12 hours (varied in the range 17 - 28 mglhour). 
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Fig 3.4 Dissolution of theophylline from granules coated with various amounts of ethylcellulose. 
+ 5% w/w Ethylcellulose 
• 10% w/w Ethylcellulose 
012.5% w/w Ethylcellulose 
x 15% w/w Ethylcellulose 
In the case of granules coated with 12.5% and 15% w/w ethylcellulose, the total amount of theophylline 
released within lOh did not exceed a maximum of 60% which indicates that such high concentrations 
should not be used unless modified by the addition of desirable channelising agents. 
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Fig. 3.5 Release rate (mglh) of theophylline from granules coated with: 
• 5% w/w Ethylcellulose 
010% w/w Ethylcellulose 
x 12.5% w/w Ethylcellulose 
o 15% w/w Ethylcellulose 
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Fig.3.6 Release rate (mglh) of theophylline from granules coated with 15% w/w of ethylcellulose. 
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Fig.3.7 Dissolution of theol?hylline from granules coated with 15% w/w of ethylceUulose over a 24 hour 
period. No significant vanations were observed from 14 hours onwards. 
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An attempt was made to overcome the above limitations by determining the release 
from granule samples consisting of a mixture of equal parts of granules coated with 
5%, 10% and 15% w/w ethy1cellulose. Five determinations were done and the 
dissolution profile showing the mean percent theophylline released with standard 
deviations against time (hours) is illustrated in Fig. 3.8. In this case after 10 hours 
nearly 70% of drug was released and a shorter lag time was shown. 
The effect of the retardation of drug release from particles coated with ethy1cellulose 
is clearly demonstrated by comparing the dissolution profile of theophylline from 
uncoated granules of the same mesh size. For the uncoated granules 90% dissolution 
was achieved after 45 minutes (Fig. 3.9). 
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Fig. 3.8 Dissolution of theophylline from a mixture of equal parts of granules coated with 5%, 10% 
and 15% w/w of ethylcellulose using water as dissolution medIUm. 
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Fig. 3.9 Dissolution of theophylline from uncoated granules. 
The percentages of drug released after 5 hours were obtained from the plots of percent 
drug dissolved versus time (hours) for each amount of coating with ethylcellulose (5%, 
10%, 12.5% and 15% w/w) (see Fig. 3.10). These percentages were plotted against 
the amount of coating (% w/w) (Fig. 3.11). The percentage of drug released after 5 
hours decreased almost linearly with increased amounts of coating material. 
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Fig. 3.10 Dissolution of theophylline from granules coated with various amounts of ethylcellulose . 
• 5% w/w ethylcellulose 
o 10% w/w ethylcellulose 
x 12.5% w/w ethylcellulose 
015% w/w ethylcellulose 
The dotted lines show the % of drug released after 5 h. 
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Fig. 3.11 The effect of increasing ethylcellulose coating amount on the percentage of theophylline 
released after 5 hours. 
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Experiments performed using phosphate buffer as the dissolution medium in place 
of distilled water produced unexpected results. The dissolution profile obtained using 
a sample consisting of a mixture of equal parts of granules coated with 5%, 10% and 
15% w/w of polymer using 0.1M phosphate buffer at pH 5.0 as dissolution medium is 
shown in Fig. 3.12. Similar profiles were obtained with phosphate buffers at pH 7.5 
and 2.5. It appears that the dissolution of theophylline in phosphate buffer is greatly 
impeded (10% was released in 8 hours). Possible reasons for the slow release of the 
drug through the ethylcellulose coating in phosphate buffer will be examined in detail 
in Chapter 6. 
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Fig 3.12 Dissolution proftie obtained from an equal part mixture of coated granules (5%, 10% and 
15% ethylcelluIose) using O.lM phosphate buffer pH 5.0 as dissolution medium. 
However it is necessary to point out at this stage that the reason for impeded release 
is not related to pH since a further similar experiment was carried out using acidified 
water (dilute HCI) at pH 2.0 and 5.0. In these cases the profiles obtained were similar 
to that achieved in distilled water. Changing the pH during the dissolution time period 
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also produced no hindrance to the dissolution process. During the first hour dissolu-
tion was carried out in acidified water (PH 2.4), then at pH 5.1 for a further 20 minutes 
and then in distilled water for the remaining period. Dissolution under these circum-
stances was not impeded. 
Scanning electron micrographs of exhausted granules remaining after the dissolution 
process are shown in Fig. 3.13. Both surface and cross sectional views are shown. The 
dissolution medium used was distilled water. 
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A Elh .cell. 15% B Elh.cell. 15% 
Surface view" 50 Cross seclion x 1000 
C Elh.cell. 10% D Elb.cell. 10% 
Surface view x 50 Cross seclion x 1000 
E Elh.cell. 5% F Elh.cell. 5% 
Surface view x 50 Cross section x 1000 
Fig. 3.13 Sca nning eleclron micrographs of exhausled granules remaining afler dissolulion lesling. The 
granules were coaled with various amounts of elhyleellulose (expressed as % w/w). 
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CHAPTER FOUR 
DEVELOPMENT OF THEOPHYLLINE MINI-TABLETS FOR CONTROLLED 
RELEASE DELIVERY: EFFECT OF COATING COMPOSITON AND DISSOLU-
TION MEDIUM ON RELEASE CHARACTERISTICS OF MINI-TABLETS 
4.1 INTRODUCTION 
The development of an ideal orally administered drug delivery system providing 
constant release of drug has been the focus of r.ecent research activity (e.g. Kiillstrand 
and Ekman, 1983; Suryakusuma and Jun, 1984; Baveja et a!., 1987). The objective is 
to provide constant drug delivery during passage through the gastrointestinal tract 
(GlT) irrespective of variations in pH, surface tension and viscosity within the GIT. 
In certain cases like theophylline, which has a narrow therapeutic range, constant 
plasma levels should be strictly maintained during the intervals between doses. 
Various attempts have been made to produce slow- release preparations of theo-
phylline. Some of these have been single-unit dosage forms (SUDF) such as tablets 
where the drug is incorporated in a polymeric matrix (McGinity et al., 1983; Cameron 
and McGinity, 1987 a and b; Nakano et aI., 1983; Parab et al., 1986), while others are 
multiple-unit dosage form (MUDF) products consisting of pellets, granules or par-
ticles which can be enclosed in gelatin capsules (Uppold and Forster, 1982; Kawashi-
ma et aI., 1985; Motycka et al., 1985; Chang and Hsiao, 1989). The MUDF products 
have definite advantages over the SUDF (Bechgaard, 1982; Beckett, 1981). Previous 
attempts at developing MUDF and SUDF preparations have not achieved the ideal 
characteristics of zero-order release between dosage intervals over almost the entire 
drug content of the dosage form, as demonstrated by numerous in vitro dissolution 
tests (Simons et al., 1984; Chung and Shim, 1987; Summers et aI., 1986; Buckton et 
al., 1988); A possible reason for non-uniform release rates of the medicament may 
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be due to the irregularity in shape of the pellets or granules. Every film-coated pellet 
or granule is different in size, shape and coating thickness, which could produce erratic 
release rates. 
In order to regularise the coated unit in respect of size, shape and coating thickness 
and to determine the resulting effect on theophylline release, mini-tablets (0.3 cm 
diameter, 20 ± 1 mg) were produced and film-coated with a variety of polymers 
(insoluble and soluble). The in vitro dissolution rate of theophylline from 20 tablets 
enclosed in a hard gelatin capsule was monitored at regular intervals over a 12 hour 
period. Differences in release profiles depending on the composition and the thick-
ness of the polymer mm are demonstrated. 
4.2 MATERIALS AND METHODS 
4.2.1 Chemicals 
Theophylline anhydrous was received from Holpro Chemical Corporation. Sodium 
carboxymethy1cellulose (Holpro Chemical Corporation) was the binder and magne-
sium stearate was the lubricant during tablet production. Ethy1cellulose 10 cps 
(Hercules Inc., Wilmington), EudragirRS 100 and Eudragi~RL 100 (Rahrn Pharma, 
Darmstadt) were chosen as the water-insoluble polymers while the water-soluble 
polymers included PEG 1540 (Riedel-De Haen AG, Seelze-Hannover) and Polysor-
bate 20 (Honeywell-Atlas, U.K). Cellulose acetate phthalate (CAP; Eastman Chemi-
® 
cal International, U.K) is soluble in dilute aqueous alkalis, while Eudragit L (Rahm 
Pharma) is soluble in a neutral to weakly alkaline milieu. Isopropanol and acetone 
(AR) were used as solvents. 
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4.2.2 Preparation of the mini-tablets 
The theophylline anhydrous powder was granulated using sodium carboxymethylcel-
lulose in the form of a 5% w/v aqueous paste. After drying the granules were 
lubricated with 0.5% w/w magnesium stearate and compressed to form 3 rtun diameter 
mini-tablets using a Manesty F3 single punch tablet machine (Manesty Machines Ltd., 
Liverpool) having an average hardness of 25 N and weighing 20 ± 1 mg. The tablet 
hardness was measured using a Erweka TBH 28 Tablet Hardness Tester, F.R.G. 
4.2.3 Film coating of mini-tablets 
Film coating using an Aeromatic AG Film Coating Dryer (bottom spray) was carried 
out under optimum carefully controlled conditions (see Table 4.1). Various batches 
of mini-tablets were coated, each differing in the composition and thickness of the 
polymeric coating mixture. 
TABLE 4.1 Coating conditions controlled during mm coating of mini-tablets by fluidised bed 
technology. 
Bed weight 
Coating solution 
Solution delivery rate 
Atomizing air pressure to spray 
Rated value drying temperature 
Drying temperature 
Outlet air temperature 
Fluidizing air flow rate 
83 
60g 
5 - 8% w/v total polymer in isopro-
panol:acetone 1:1 
8 - 10 mIJmin 
2 2 kgicm 
55°C 
60°C 
4SOC 
3 100 - 120 m !h 
4.2.4 Assay for theophylline content 
The theophylline released into the dissolution medium was, after suitable dilution, 
assayed by UV spectrophotometric determinations of absorbance measured at 271 
nm using a Beckman Model 25 Spectrophotometer (Beckman Instruments Co., 
Irvine). 
4.2.5 Drug dissolution studies 
The USP XXI paddle method was utilised for in vitro dissolution studies of theo-
phylline from 20 coated mini-tablets enclosed in a hard gelatin capsule (size 0). 
Apparatus used was a Hanson Dissolution Drive Control and Multiple Spindle Drive 
(Northridge, Ca) with a constant temperature water bath at 37 ± O.5°C. Deionized 
water (PH 6.8), Simulated Intestinal Fluid USP XXI without pancreatin (PH 7.5) and 
Simulated Gastric Fluid USP XXI without enzymes (PH 1.2) at volumes of 900 mL 
were used as dissolution media. The paddles' rotational speed was 50 ± 1 rpm. The 
encapsulated mini-tablet samples were contained in mesh stainless-steel baskets, 
which were firmly attached to the holders by means of spring steel clips. Determina-
tions were carried out in triplicate in most cases and the mean values calculated for 
plotting. Suitable volumes (about 2 mL) of dissolution medium were removed at 
appropriate intervals, filtered through a membrane filter (0.22,um), a 1 mL aliquot 
diluted and the absorbance measured at 271 nm. An equal volume of dissolution 
medium at 37°C was added to maintain constant volume. 
4.2.6 Scanning electron microscopy 
Photomicrographs of fractured mini-tablets of different coating thickness were taken 
using a JI~OL JSM 840 Scanning Electron Microscope at magnification 25 X and 500 
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X, as well as a surface view at 25 X. Samples were sputter-coated with gold prior to 
microscopic examination. 
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4.3 RESULTS AND DISCUSSION 
The release in vitro of theophylline from samples of encapsulated film coated mini-
tablets from batches differing in composition and thickness of the polymeric coating 
mixture was investigated and percent drug released as a function of time was calcu-
lated. Some batches were coated with ethylcellulose only (no channelizing agent) at 
amounts of 5%,7.5% and 10% w/w, while others coated with ethylcellulose contained 
a water-soluble polymer (eg. PEG 1540 and polysorbate 20) as a channelizing agent 
in the ratio of ethylcellulose: water-soluble polymer 2:1. Batches were also coated 
with the insoluble but permeable polymethacrylate materials EudragirRL 100 and 
Eudragi~S 100. No channelizing agents were incorporated in these polymethacry-
late materials. 
Dissolution of theophylline from mini-tablets coated with ethylcellulose only (5%, 
7.5% and 10%) was not significant even after 6 hours when using deionised water as 
dissolution medium. The diffusion of water and drug through the ethylcellulose 
membrane was too slow for any meaningful release to occur. However the release of 
theophylline was greatly enhanced by the presence of soluble channelizing agents. 
The dissolution profiles for mini-tablets coated with ethylcellulose and PEG 1540 at 
different amounts using deionised water as dissolution medium are shown in Fig. 4.1 
where the effect of thickness on the initial lag period (time for water to pass through 
the membrane to the drug core) is clearly demonstrated. 
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Fig. 4.1 % Theophylline dissolved as a function of time from mini-tablets coated with ethylcellulose 
and PEG 1540 (2:1) at amounts expressed as % w/w. Dissolution medium: water . 
• Ethylcellulose 1.7% + PEG 0.85% 
... Ethylcellulose 3.3% + PEG 1.7% 
"" . Ethylcellulose 5.0% + PEG 2.5% 
" Ethylcellulose 5.0% (No PEG) 
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Fig. 4.2 % Theophylline dissolved as a function of time from a mixture of 20 mini-tablets coated with 
different amounts (% w/w) of an ethylcellulose:PEG 1540 (2:1) mixture. Vertical bars indicate 
approximate S.D. Dissolution medium: water.The mini-tablet mixture per capsule consisted of e th.cell. 
1.7% + PEG 0.85% 2 tablets, eth.cell. 3.3% + PEG 1.7% 3 tablets, eth.cell. 5% + PEG 2.5% 6 tablets, 
and eth.cell. 5% (NO PEG) 4 tablets. 
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The initial leaching away of the soluble PEG creates channels or pores in the 
ethylcellulose membrane during the initial lag period during which time no significant 
release occurs. When the pores are formed the dissolved drug passes rapidly through 
into the dissolution medium until over 95% of the drug is released. The following 
approximate times (h) were require~ to achieve 95% release. 
Mini-tablets coated with: 
ethylcellulose 1.7% + PEG 0.85% 3 h 
ethylcellulose 3.3% + PEG 1.7% 5 h 
ethylcellulose 5.0% + PEG 2.5% 8 h 
The mini-tablets coated with ethylcellulose 5.0% (NO PEG) released only aboutSO% 
of drug after 10 hours. 
By the selection of a definite number of mini-tablets from each coating thickness 
making a total of20 mini-tablets enclosed in a hard gelatin capsule (size 1), a constant 
release profile could be obtained (Fig. 4.2). Theophylline dissolution profiles are 
shown for mini-tablets coated with ethylcellulose containing EudragifL, CAP and 
polysorbate 20 (Figs. 4.3, 4.4 and 4.5 respectively). Again it appears in each instance 
that after an initial lag period (during which time pores are formed as a result of the 
leaching of the soluble component), there is a gradual release of drug into the 
dissolution medium up to 95% in certain instances of the total drug content. This is 
considerably higher than total release for some of the commercially available sus-
tained release preparations of theophylline (eg. Simons et al., 1984). It was noted, 
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however, that the rate of drug dissolution into simulated intestinal fluid was signifi-
cantly reduced under identical hydrodynamic conditions. 
This reduction in dissolution rate may be due to molecular interaction at the core-coat 
interface between theophylline and the phosphate ions leading to the inhibition of the 
transport process. A fuller discussion of the reasons for this reduced drug release will 
be presented in chapter 6. 
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Fig. 4.3 % Theophylline dissolved as a function of time from mini-tablets coated with ethylcellulose 
and Eudragil"L (2:1) at amounts expressed as % w/w. Dissolution medium in parenthesis. 
o Ethylcellulose 2% + EudragirL 1% (water) 
+ Ethylcellulose 3% + Eudragit"l1.5% (water) 
• Ethylcellulose 3% + Eudragi?L 1.5% (Sim.Int.Fl.pH 7.5) 
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Fig. 4.4 % Theophylline dissolved as a function of time from mini-tablets coated with ethylcellulose 
and CA.P. (2:1) at amounts expressed as % w/w. Dissolution medium in parenthesis. 
x Ethylcellulose 2% + c.A.P. 1 % (water) 
+ Ethylcellulose 3% + C.A.P. 1.5% (water) 
• Ethylcellulose 2% + CA.P. 1% (Sim.Int.Fl.) 
a Ethylcellulose 3% + CA.P. 1.5% (Sim.Int.Fl.) 
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Fig. 4.5 % Theophylline dissolved as a function of time from mini-tablets coated with ethylcellulose 
and Polysorbate 20 (2:1) at amounts e~ressed as % w/w. Dissolution medium in parenthesis. 
~ Ethylcellulose 2% + Polysorbate 20 1% (water) 
+ Ethylcellulose 3% + Polysorbate 20 1.5% (water) 
• Ethylcellulose 4% + Polysorbate 20 2% (water) 
p Ethylcellulose 2% + Polysorbate 20 1% (Sim.Int.Fl.) 
x Ethylcellulose 3% + Polysorbate 20 1.5% (Sim.Int.Fl.) 
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Fig. 4.6 % Theophylline dissolved as a function of time from mini-tablets coated with EudragirRL 
and RS at amounts expressed as % w/w. Dissolution medium: water. 
.aEudragirRL 2% D Eudragit~S 2% 
+ EudragirRL 4% 
• Eudragir'RL 6% 
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x EudragirRS 4% 
<> Eudragit"RS 6% 
It is noteworthy that for equivalent coating amounts the mini- tablets coated with 
Eudragit'\L and Eudragi~S produced dissolution curves with a shorter lag period 
and generally a more constant rate of release (Fig. 4.6) compared with those coated 
with ethyl cellulose. As expected the EudragirRL films by virtue of the content of 
• 
quaternary ammonium groups it cpntains are, in contrast to Eudragit<BkS, freely 
permeable to water and dissolved drugs. The in vitro dissolution profile for mini-ta-
blets coated with Eudragi~L confirms this fact. 
Electronmicrographs of EudragitBRS - coated mini-tablets show the uniformity of the 
polymer film coatings around the tablet (Fig. 4.7) illustrating the reproducibility and 
efficiency of this coating method. 
Utilising mini-tablets coated with various amounts of ethylcellulose and PEG 1540 
(2:1) the dissolution of theophylline from capsules containing specifically selected 
numbers of film coated mini-tablets at various thicknesses was monitored. These in 
vitro dissolution profiles from various mini-tablet mixtures are shown in Figs. 4.8, 4.9, 
4.10 and 4.11. 
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Fig. 4.7 SEM's of fractured mIDi-tablets coated 
with various amounts of EUdragit®RS seen in 
cross-sectional view. MagnificatIOn x 500. 
A: 2% w/w coating 
E: 4% w/w coating 
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FigA.8 Dissolution promes of theophylline from mini- tablet mixtures coated with ethylcellulose and 
PEG 1540 (2:1) in various amounts expressed as % w/w. Dissolution medium: water. 
{
th.cell. 1.7% + PEG 0.85% 5 mIDi-tablets Eth.cell. 1.7% + PEG 0.85% 4 mini-tablets 
1- Eth.ccll_ 3.3% + PEG 1.7% 5 mini-tablets .,. Eth.ccll.3.3% + PEG 1.7% 4 mini-tablets 
Eth.ccll.5.0% + PEG 2.5% 5 mini-tablets Eth.cell. 5.0% + PEG 2.5% 4 mini-tablets 
Eth.ccll. 5.0% (no PEG) 4 mini-tablets 
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Fig. 4.9 Dissolution profIles of theophylline from mini- tablet mixtures coated with Ethylcellulose and 
PEG (2:1) in various amounts expressed as % w/w. Dissolution medium: water. 
Eth.cell. 1.7% + PEG 0.85% 2 mini-tablets 
Etb.cell. 3.3% + PEG 1.7% 3 mini-tablets 
Etb.cell. 5.0% + PEG 2.5% 5 mini-tablets 
Etb.cell. 5.0% (No PEG) 5 mini-tablets 
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Eth.cell. 1.7% + PEG 0.85% 2 mini-tablets 
Etb.cell. 3.3% + PEG 1.7% 3 mini-tablets 
Eth.cell. 5.0% + PEG 2.5% 6 mini-tablets 
Eth.cell. 5% (No PEG) 4 mini-tablets 
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Fig. 4.10 Dissolution profiles of theophylline from mini- tablet mixtures coated with etbylceUulose and 
PEG (2:1) in various amounts expressed as % w/w. Dissolution medium: water. 
Eth.ceU. 1.7% + PEG 0.85% 2 mini-tablets Eth.cell. 1.7% + PEG 0.85% 2 mini-tablets 
Eth.ceU. 3.3% + PEG 1.7% 2 mini-tablets Eth.cell. 3.3% + PEG 1.7% 2 mini-tablets 
Eth.ceU. 5.0% + PEG 2.5% 5 mini-tablets Eth.cell. 5.0% + PEG 2.5% 4 mini-tablets 
Eth.ceU. 5.0% (No PEG) 6 mini-tablets Eth.ceU. 5.0% (no PEG) 7 mini-tablets 
Eth.ceU. 1.7% + PEG 0.85% 2 mini-tablets 
Eth.ceU. 3.3% + PEG 1.7% 3 mini-tablets 
Eth.ceU. 5.0% + PEG 2.5% 4 mini-tablets 
Eth.ceU. 5.0% (No PEG) 6 mini-tablets 
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Fig. 4.11 Dissolution promes of theophylline from mini- tablet mixtures coated with ethylcellulose and 
PEG (2:1) in various amounts expressed as % w/w. Dissolution medium: water. 
) 
Eth.cell. 1.7% + PEG 0.85% 2 mini-tablets Eth.cell. 1.7% + PEG 0.85% 3 mini-tablets 
t Eth.cell. 3.3% + PEG 1.7% 6 mini-tablets Eth.cell. 3.3% + PEG 1.7% 4 mini-tablets 
a 
Eth.cell. 5.0% + PEG 2.5% 7 mini-tablets Eth.cell. 5.0% + PEG 2.5% 6 min-tablets 
1Eth.ell. 1.7% + PEG 0.85% 2 mini-tablets Eth.cell. 3.3% + PEG 1.7% 5 mini-tablets Eth.cell. 5.0% + PEG 2.5% 8 mini-tablets 
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Eth.cell. 5.0% (no PEG) 2 mini-tablets 
By carefully adjusting the exact number of mini-tablets of each thickness, various 
dissolution profiles can be obtained and Fig. 4.12 shows the combination producing 
the most constant drug release using water as dissolution medium. Similarly mini-ta-
blets coated with various amounts of Eudragi~S and RL were combined in certain 
• 
numbers (Fig. 4.13). 
Batches of mini-tablets of theophylline were also film coated with a polymeric mixture 
of EudragirRS and ethylcellulose (6: 1) at three thicknesses. The dissolution profiles 
are shown in Fig. 4.14. Specific mini-tablet combinations of various coating thick-
nesses of these were also investigated (Fig. 4.13). Similarly combinations of Eu-
dragirRL and ethylcellulose (3:1) were prepared and dissolution profiles produced 
(Fig. 4.15). 
Dissolution tests were also carried out under the same hydrodynamic conditions on a 
commercially available controlled release preparation (Theo-Du?tablets 300 mg and 
200 mg) (Figs. 4.16 and 4.17). In these cases the release was up to about 70% of the 
total drug content after 12 hours. Moreover the release appeared to be biphasic, an 
initial peak at 1 hour and then a second at 8 hours. When simulated intestinal fluid 
(PH 7.5) was used as the dissolution medium in place of water, the rate at which the 
theophylline was released was significantly greater (see Fig. 4.17). This may be due 
to the fact that theophylline is more soluble in an alkaline medium. 
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Fig. 4.12 Dissolution profIles of theophylline from mini- tablet mixture coated with ethylcellulose and 
PEG (2:1) in various amounts expressed as % w/w. Dissolution medium: water. Vertical bars indicate 
approximate S.D. 
Ethylcellulose 1.7% + PEG 0.85% 2 mini-tablets 
Ethylcellulose 3.3% + PEG 1.77% 4 mini-tablets 
Ethylcellulose 5.0% + PEG 2.5% 4 mini-tablets 
EthylceUulose 5.0% (No PEG) 5 mini-tablets 
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Fig. 4.13 Dissolution profLIes of theophylline from mini- tablet mixtures coated with Eudragit" RS, 
Eudragit""RL and Eudragit"'RS + Ethylcellulose (6:1) in various amounts expressed as % w/w. 
Dissolution medium: water. 
-t" / Eudragit~L 6% 4 mini-tablets; and 
l Eudragi? RS 4% 16 mini-tablets 
"") Eudragit~L 6% 5 mini-tablets; and 
LEudragiC"RS 4% 15 mini-tablets 
fEudragir RS 2% + Eth.cell. 0.33% 4 mini-tablets 
o \. Eudragil'RS 4% + Eth.cell. 0.67% 16 mini-tablets 
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Fig. 4.14 Dissolution profiles of theophylline from mini- tablets coated with mixture of Eudragit"'RS 
and EthylceUulose (6:1) in various amounts expressed as % w/w. Dissolution medium: water. 
+ Eudragit"'RS 6% + EthylceUulose 1% 
*Eudragit'RS 4% + EthylceUulose 0.67% 
aEudragit'RS 2% + EthylceUulose 0.33% 
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Fig. 4.15 Dissolution proflles of theophylline from mini- tablets coated with a mixture of Eudragit"RL 
and EthylceUulose (3:1) in various amounts expressed as % w/w. Dissolution medium: water. 
-i" Eudragi1"RL 6% + EthylceUulose 2% 
"Eudragi('RL 4% + EthylceUulose 1.33% 
o Eudragit'RL 2% + EthylceUulose 0.67% 
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Fig. 4.16 Dissolution profIles of theophylline (% released and release rates) from Theo-Dur<lJoo mg 
tablets. Vertical bars mdicate approxunate S.D. Dissolution medium: water. 
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Fig.4.17 Dissolution proftles of theophylline from Theo- Duhoo mg tablets. Vertical bars indicate 
approximate S.D. 
+ Percentage drug dissolved and release rate (mglh) using water as dissolution medium 
• Percentage drug dissolved and release rate (mglh) using simulated intestinal fluid U.S.P. (pH 7.5) 
as dissolution medium. 
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Plain, uncoated mini-tablets were compressed to various hardnesses (25 N, 15 Nand 
10 N) to investigate the effect of compression force on the dissolution rate. The 
differences in dissolution rate were so slight that it was concluded that hardness was 
not a significant factor influencing the dissolution of theophylline from the mini-ta-
o 
blets. The dissolution curve for miJ1i-tablets with a hardness of 25 N is shown in Fig. 
4.18. 
It is expected that not every film coated mini-tablet will release the drug at exactly the 
same rate within a particular batch due to slight imperfections or uneveness of coating 
in individual mini-tablets. To assess the degree to which each mini-tablet varied in 
this respect, in vitro dissolution tests were carried out on individual mini-tablets film 
coated with ethy1cellu1ose 3.3% w/w and PEG 1540 1.7% w/wand the tlO% (time for 
10% of drug release in minutes) of each mini-tablet was determined (see Fig. 4.19). 
The tlO% of the most rapid releasing mini-tablet was about 90 minutes while the 
slowest was about 150 minutes (mean 120.6 ± 22 minutes). This demonstrates signi-
ficant variability between individual mini- tablets, however in a hard gelatin capsule 
containing 20 mini- tablets these differences may not be significant. 
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Fig. 4.18 Dissolution profile of theophylline from uncoated nllni-tablets compressed to a hardoess of 
25N. 
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Fig. 4.19 Dissolution profiles of 10 mini-tablets coated with 3.3% w/w ethylcellulose and 1.7% w/w 
PEG 1540 deternllned individually to show the difference in the t 10% (time in minutes for 10% of 
drug release) 
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Effects of variation in pH of dissolution medium on drug release 
Dissolution tests carried out show the importance of the composition of the dissolu-
tion medium used. We have seen that simulated intestinal fluid pH 7.5 (no enzymes) 
hinders the dissolution process from film coated mini-tablets when both ethylcellu-
lose and the Eudragitiilare used as film coating material. Simulated gastric fluid 
(without enzymes) however allows dissolution to proceed normally. The pa of the 
medium itself could not be the reason for retarded release since identical tests were 
carried out using dilute NaOH (PH 7.4) and there was only a small difference from 
when water is used. Dissolution tests were also carried out using dilute Hel (PH 2.0) 
for the first hour, then NaOH solution added to raise the pH to 4.0 for the second 
hour, to pH 6.0 for the third hour, and then finally pH 7.5 from the fourth hour 
onwards. Once again dissolution was not significantly different from the situation 
when water is used as the dissolution medium. 
Further electronmicrographs (Fig. 4.20) show surface views of film coated mini-ta-
blets at various magnifications, as well as cross sectional views of fractured mini-ta-
blets showing clearly the uniformity of the film coating around mini-tablets. 
This work has demonstrated the importance of slight variation in coating composition 
on drug release from film coated tablets. 
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A Eth.cell. 5% coating 
(surface view x 200) 
C Eth.cell. 5% coating 
(surface view x 27) 
E Eth.cell. 5% coating 
(cross section x 25) 
B EudragihS 6% coating 
(surface view x 200) 
D Eudragil'RS 4% coating 
(surface view x 25) 
F Eudragil'RS 6% coating 
(cross section x 27) 
Fig. 4.20 Scanning electron micrographs of mini-tablets fUm coated with various polymers expressed 
as % w/w. Both surface and cross sectional views through fractured mini-tablets are shown. 
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However it is important to note that release of up to 95% of total drug content is 
achievable by the selection of a suitable polymeric mixture to uniformly film coat 
individual batches of mini-tablets. By selecting definite numbers of mini-tablets and 
enclosing them in a hard gelatin capsule, the desired modified- release characteristics 
• 
with good reproducibility may be co.nsistently achieved. 
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CHAPTER FIVE 
CHANGES IN DRUG RELEASE RATE: EFFECT OF STRESS STORAGE CON-
DITIONS ON POLYMERIC FILM COATED MINI-TABLETS 
5.1 INTRODUCTION 
The practice of coating powder, p~llets; granules and tablets with a thin film of a 
polymeric material in order to perform a specific pharmaceutical function is becoming 
increasingly widespread (Rowe, 1985; Porter and Hogan, 1984). This increasing 
popularity is due mainly to recent advances in fluidised bed processes and to the 
development of both aqueous and organic solvent-based polymeric coating systems. 
Besides providing a protective coating to the dosage form, the film coating may be 
effective in controlling both the rate of drug release ( controlled release preparations) 
and the time of release depending on the pH of the gastro-intestinal millieu (enteric 
coatings) (Lehmann et al., 1976; Lindholm et al., 1986; Suryakusuma and Jun, 1984; 
Lehmann, 1975; Kiillstrand and Ekman, 1983; Li et aI., 1988; and Benita and Don-
brow, 1982). 
In controlled release systems the rate at which the drug is released through the outer 
film coating is often the rate limiting step for bioavailability. The dissolution profiles 
of these drug delivery sytems are usually determined in vitro soon after manufacture. 
Pharmaceuticals normally experience a shelf life and it is necessary therefore to 
determine what effect changes in the ambient conditions during the shelf life will have 
on the ultimate release of the drug at the time of use. The two environmental variables 
chosen for this investigation were temperature and relative humidity (RH). 
An investigation into the effect of storing film coated mini-tablets at varying tempera-
tures am! relative humidities on the rate of drug release was carried out. Previous 
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workers (Hoblitzell et al., 1985) demonstrated the effects of ageing by storing 
enteric-coated aspirin tablets at different temperatures and relative humidities. They 
demonstrated that there were significant differences in dissolution profiles and 
dissolution efficiencies depending on storage conditions, storage time and types of 
packages in which the enteric-coated aspirin tablets were packed. Dissolution times 
increased significantly and it was suggested that temperature is the primary factor 
causing ''baking'' of the coating resulting in dissolution being impeded. The tablets 
used by Hoblitzell et al. (1985) possessed a shellac type enteric coating. 
In this study the effects of stress storage conditions for relatively short to long time 
periods on theophylline mini-tablets are reported. The mini- tablets were film coated 
with polymeric agents commonly used in the pharmaceutical industry such as ethylcel-
lulose and polymers of methacrylic acid esters. 
5.2 MATERIALS, METHODS AND EQUIPMENT 
5.2.1 Preparation of Film Coated Mini-tablets 
Theophylline anhydrous obtained from Holpro Chemical Corporation was used to 
prepare mini-tablets (3mm in diameter) by the methods described in the previous 
sections. Small batches of mini-tablets were film coated using an Aeromatic Film 
Coating Dryer (Switzerland) by the upward spray method. Optimum conditions were 
maintained to obtain smooth uniform coatings. Table 5.1 shows the compositions of 
the coating materials and their amounts expressed as percent w/w. 
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Table 5.1 Composition of the coating materials and the amount of coatings expressed as % w/w. 
Coating Composition Amount of coating (% w/w)· 
Eudragi~RL 1.5 and 3.0 
Ethylcellulose + PEG 1540 (2:1) 0.5 + 0.25 and 1.0 + 0.5 
Ethylcellulose + Eudragi'lt (2:1) 1.0 + 0.5 and 2.0 + 1.0 
• • ±S D of amount of polymer coatmg was always less than 0.15. 
The Eudragit~were obtained from R6hm Pharrna, Darmstadt, and the ethyJcelluJose 
(NF grade) 10 cps from Hercules, Wilmington. The polyethylene glycol 1540 was 
supplied by Riedel-De Haen AG, Seelze-Hannover. Acetone and isopropanol (ana-
lytical grade) were used as solvents in the coating process and were used as received. 
5.2.2 In vitro Dissolution 
The dissolution tests were conducted using apparatus II of the USP XXI. The paddles 
were driven by a multiple-spindle drive (Hanson Research Corporation, Northridge, 
Ca.) at a rotational speed of 50 ± 1 rpm. Distilled water (lL) was the dissolution 
medium at 37 ±O.5'C. Samples consisting of ten coated mini-tablets were contained 
in the wire mesh basket. Samples of dissolution medium were removed at regular 
time intervals, diluted, and assayed for theophylline by UV spectrophotometry at 271 
nrn. Distilled water at 37'C was added in order to maintain constant volume. 
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5.2.3 Experimental Storage Conditions 
Samples consisting of about 10 g of film coated mini-tablets of each coating material 
and thickness were contained in open petri dishes and subjected to the following 
experimental conditions: 
1. Isothermal storage at zgoC, 35°C and 45°C with the RH. maintained constant at 
between 55 - 60%. 
2. Cyclic conditions: 
(i) Samples were exposed to 45°C at 55% RH. for 24 hours, then at 28°C and 20% 
RH. for 24 hours, and then at 5°C and 10% RH. for 24 hours after which the 
cycle was repeated. 
(ii) Exposure alternating every 24 hours between 45°C and 55% RH., and 28°C 
and O%RH. 
The relative humidity was controlled within ±5% by storing the samples in dessicators 
containing appropriate mixtures of sulphuric acid and water (In: CRC Handbook of 
Chemistry and Physics, 60th Edition, R.C. Weast (ed.), CRCPress, Florida, (1981) pp 
E46, F7). The complete absence of moisture was produced using phosphorous 
pentoxide. Temperature control was achieved using incubators set at 28°C, 35°C, and 
45°C, and a refrigerator for 5°C. To facilitate subsequent dissolution measurements, 
coating and storage of samples was staggered at one week intervals. 
Samples were submitted to dissolution testing 24 - 48 hours after coating (initial 
profile), and then dissolution profiles obtained after 21, 90 and 180 days under 
, 
isothermal conditions and after 90 days of cyclical storage. 
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5.3 RESULTS AND DISCUSSION 
The dissolution profiles of the mini-tablet samples exposed to stress storage condi-
tions showing the percentage theophylline released as a function of time in hours (h) 
are shown in Figs. 5.1 a to I and 5.2 a to f. From each dissolution curve, the time in 
hours for 50% release of theophylline (t50%) was obtained and these results are 
tabulated (see Table 5.2). These dissolution curves and t50% values demonstrate that 
a similar change in drug release pattern occurs which is irrespective of the nature of 
the polymeric film. The ageing process brought about by storage under stress condi-
tions tended to impede the dissolution process. 
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Fig. 5.1 Changes in drug release promes resulting from the exposure of mini-tablets fUm coated with 
various polymeric materials to isothermal stress storage conditions for periods of 21 days and 90 days. 
+, Initial prome 24 h after coating; " 28°C; c, 35°C; X,45°C. 
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Fig. 5.1 Changes in drug release profUes resulting from the exposure of mini-tablets filin coated with 
various polymeric materials to isothermal stress storage conditions for periods of 21 days and 90 days. 
+, Initial profile 24 h after coating;', 28'C;o, 35'C; X, 45'C. 
114 
100 
90 
80 
" 70 
0 
I 60 
• 
• 60 
0 
I 40 
v 
• 30 d 
20 
10 
0 
0 
100 
90 
80 
.. 70 
0 
I 60 
• 
• 50 
0 
I 40 
v 
• 30 d 
20 
10 
0 
0 
100 
90 
80 
" 70 
0 
I 60 
• 
• 50 
0 
I 40 
v 
• 30 d 
20 
10 
0 
0 
0.25 0.5 0.76 1 1.25 1. 5 1.75 2 2.25 2.5 
0.25 0.5 
0.5 
Time (Hours) 
g. Elh.cell. 1"" • PEG 0 .5'" (21 day_) 
0 .75 1.25 1.5 1.75 2 2.25 2.5 2.75 3 
Time (Hours) 
h. Elh.ceU. 1" • PEG 0.5'.' (90 dayl ) 
1 1.5 
Time (Hours) 
I.Elh.cell .1'1i • Eudt aglt L 0,5'4 (21d aya) 
2 2.5 
Fig.5.1 Changes in drug release proflles resulting from the exposure of mini-tablets ftlm coated with 
various polymeric materials to isothermal stress storage conditions for periods of 21 days and 90 days. 
+. Initial profile 24 h after coating; ' . 28°C; o. 35°C; X. 45°C. 
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Fig. 5.1 Changes in drug release profiles resulting from the exposure of mini-tablets fUm coated with 
various polymeric materials to isothermal stress storage conditions for periods of 21 days and 90 days. 
+. Initial profIle 24 h after coating; '. 28°C; a. 35°C; X, 45"C. 
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Fig. S.2 Changes in drug release promes after storage of mini-tablets fUm coated with various polymeric 
materials (% wlw) under experimental conditions: +, Initial (before exposure); ., cyclic4SoC/280ClSoC 
90 days; ", 28°C 180 days; X, 3SoC 180 days; () , 4SoC 180 days. 
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Fig. 5.2 Changes in drug release profiles after storage of mini-tablets film coated with various polymeric 
materials (% w/w) under experimental conditions: +, Initial (before exposure) ; " cyclic 4SOC/28°C/5°C 
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TABLE 5.2 The time in bours for 50% release of theophylline (t50%) obtained from dissolution profiles of mini-tablets coated with various polymeric materials. 
Coating composition Initial Isothermal Isothermal Isothermal Cyclic Cyclic 
of the mini-tablets value 28°C 55% R.H. 35°C 55% R.H. 45°C 55% R.H. 45°C 55% R.H. 45°C 55% R.H. 
28°C 20% R.H. 28°CO%R.H. 
5°ClO%R.H. 
. . . . . 
210 90D 180D 210 90D 180D 210 90D 1800 900 900 
Ethylcellulose 1% 1.1 1.3 1.4 1.6 1.4 1.6 1.7 1.6 2.1 2.3 1.5 1.5 
+ PEG 1540 0.5% 
~ Ethylcellulose 0.5% 0.6 0.8 1.0 1.1 1.0 1.2 1.3 1.1 1.4 1.5 1.0 1.1 
~ 
LD + PEG 1540 0.25% 
EudragihL 3% 1.5 1.7 2.0 2.5 2.2 2.6 2.8 2.7 3.0 3.2 2.2 2.3 
Eudragit"RL 1.5% 0.7 0.8 1.1 1.2 1.1 1.3 1.4 1.3 1.6 1.8 1.2 1.3 
Ethylcellulose 2% 2.4 2.8 3.6 3.9 3.2 4.0 4.2 4.2 5.0 5.1 3.8 3.8 
+ Eudragit'- 1 % 
Ethylcellulose 1 % 1.2 1.5 1.6 1.7 1.6 1.7 1.8 1.8 2.0 2.3 1.6 1.7 
+ Eudragift 0.5% 
.D = days 
There is no evidence in the Ii terature to suggest that these moderate storage condi-
tions could produce any physical or chemical changes to the anhydrous theophylline 
which comprises the tablet core. Hence the decrease in the rate of release is therefore 
presumably due to the slowing in the rate of molecular diffusion of the drug across 
the polymeric coating material. Support for this assumption is provided by recently 
published work (Okhamafe and York, 1985; Okhamafe and York, 1987) in which it is 
suggested that the permeability of polymer systems may be significantly altered by 
changes in crystallinity, glass transition temperature, polarity, degree of cross-linking 
and the binding of drugs with some of the functional groups of the polymer. It is likely 
that such changes in certain of these parameters will occur in the film coatings during 
the experimental storage period thus causing the dissolution process to be impeded. 
The intention of these tests under conditions of continual stress was to determine the 
integrity of the film coating. Internal stresses may build up in the film due to 
differences in the relative thermal expansion of the coating and the substrate. If these 
stresses exceed the cohesive strength of the film then cracking and loss of film integrity 
occurs (Rowe, 1985). This would manifest itself by a faster than expected drug release 
profile, or even an "immediate release" caused by the entire splitting of the coat. This 
can lead to toxicity or variable bioavailability. However the dissolution curves clearly 
demonstrate that the integrity of each of the film coatings was maintained even though 
there are differences in the chemical structures of the polymers used. There was no 
evidence of cracking or splitting even in the thinner films. 
It is apparent from the t50% values in Table 5.2 that the greatest reduction in release 
rate occurs in the first 21 days (isothermal storage) after coating. Although there are 
further reductions in the release rates at 90 days and 180 days these changes appear 
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to become less significant upon prolonged storage. This would suggest that the 
mechanism responsible for impeded dissolution would eventually achieve equili-
brium. 
It is also clear that the mechanism responsible for reducing drug release is tempera-
ture related since the degree to which the drug was impeded became greater as the 
storage temperature increased. It would appear that the effect of the variable hu-
midity was insignificant. Samples stored under cyclic conditions for 90 days tended 
to release the drug faster that those samples stored isothermally at 28°C, although it 
is probable that this release rate would have been slower than that for 28°C had the 
samples been stored for 180 days. 
There was only a slight difference between the release rates determined for both 
storage procedures under cyclic conditions. This demonstrates that temperature has 
a significant effect on the retardation of release as the dissolution profiles obtained 
for samples stored under cyclic conditions corresponded approximately to the average 
temperature during storage. 
It is assumed that any change in in vitro dissolution rate will also produce a con;espond-
ing change in drug release in vivo. Therefore it is considered important that film coated 
oral dosage systems, which release the drug by diffusion through a polymeric mem-
brane, should undergo in vitro dissolution testing after programmed storage periods 
(simulating the shelf life) so that a more realistic assessment of release may be 
achieved. 
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CHAPTER SIX 
DISSOLUTION OF THEOPHYLLINE FROM FILM COATED SLOW RELEASE 
MINI-TABLETS IN VARIOUS DISSOLUTION MEDIA AND AN IN VIVO COM-
PARISON USING AN ANIMAL MODEL 
6.1 INTRODUCTION 
Modern pharmaceutical technology allows the design of oral dosage forms that modify 
the bioavailability of a drug by retarding the rate of dissolution so that this becomes 
the rate-limiting step. pH is a major variable affecting this but dissolution test data 
are also influenced by mechanical, chemical and physical factors associated with either 
the apparatus itself or its environment (Prasad et al., 1982; Mazuel et al., 1983). 
Although dissolution testing has not replaced in vivo bioavailability assessment it can 
be a valuable tool to predict in vivo performance of a dosage form. If bioavailability 
problems exist with a drug, this commonly reflects continued absorption for only a 
limited time after ingestion. This places an upper time limit on the dissolution process 
in the gut, if the total amount of drug absorbed is to be maximised. Attempts to 
correlate in vivo/in vitro performance for tablets commonly involve either the time for 
a specified fraction (usually 50%) of drug content to dissolve, or the amount of the 
total dose content which dissolves in a specified time. During the dosage form design 
programme for the development of a multiple unit mini-tablet controlled release 
system an investigation of the effect of various recommended dissolution media (USP 
XXI) on the release profiles of those tablets was initiated. An animal model was also 
employed together with the in vitro studies, to assess the in vivo performance of the 
dosage forms. 
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6.2 MATERIALS AND METIIOD 
Theophylline (anhydrous) BP quality was used. Ethylcellulose was obtained from the 
Hercules Company, UK, and PEG 1540 and magnesium stearate were from BDH 
Chemicals Ltd. Isopropanol and acetone were reagent grade, and sodrum carboxy-
methylcellulose (Holpro Chemical Corporation) was used as a binder. A series of 
B.S. sieves and a mechanical sieve shaker were used for particle size selection. A 
Manesty Type F3 tableting machine with 3 mm diameter concave punches was used 
for compression. Breaking strength was measured on an Erweka testing machine. An 
Aeromatic fluidized bed (Size 1, laboratory unit, capacity 1- 2 kg) was used for coating. 
The USP XXI dissolution apparatus (paddle method) used was from Hanson Re-
search Corp., Northridge, Ca. Male, white New Zealand rabbits, 2.8 - 3.5 kg were 
used for in vivo studies. 
6.2.1 Solution properties 
The solubility of theophylline in various solvents was determined by adding excess 
drug to the solvent. The solutions were mixed overnight at 25 ± o.soC to achieve 
saturation, then filtered through a 0.22,um filter and measured spectrophotometrically 
at 271 nm. Solubilities were (mol/L): 0.0458 (water, pH 5.8), 0.0469 (HCl, pH 6), 
0.0455 (HCl, pH 1.2), 0.0462 and 0.0468 (phosphate buffers pH 5.4 and 7.4, respec-
tively). Kinematic viscosities of the dissolution media were measured at 25 ± O.2°C 
by the standard capillary-tube Ostwald viscometer. Values were (x 10' 6m2s): 0.892 
(HCI, pH 1.2), 0.889 and 0.888 (phosphate buffers pH 5.4 and 7.4). Density was 
determined by weighing a known volume of the solution at 25 ± 0.2°C. 
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6.2.2 Preparation of tablets 
Sodium carboxymethylcellulose (5% w/v) in water was added to the theophylline 
powder in a Turbula mixer, and blended for 7 min; the wet mass was then passed 
through a 16 mesh (1.0 mm) screen sieve in an oscillating granulator and dried. The 
granules were sieved and the fraction finer than 2oo I'm was lubricated in the cube 
mixer with 0.5% w/w magnesium stearate for 5 min. Bi-convex mini-tablets weighing 
22 ± 1 mg (3 mm diameter x 2 mm thick) having an average breaking strength of 26 
N, and containing appoximately 20 mg of drug, were produced by compressing the 
granules. Tablets were coated by fluid bed technology using an ethylcellulose-PEG 
mixture in equal parts of acetone and isopropanol as a coating solution. The condi-
tions for optimum film coating and thickness are given in Table 6.1. 
Table 6.1 The process conditions for optimum film coating 
Bed weight 
• Coating solution 
Solution delivery rate 
Atomizing air pressure to spray 
Rated value drying temperature 
Drying temperature 
Outlet air temperature 
Fluidizing air flow rate 
60g 
Film former in isopropanol acetone 1:1 
8 - 10 mL/rnin 
2 2 kg/em 
55°C 
60°C 
45°C 
3 100 -120 m !h 
• The film former used in this study was 5%w/v ethylcellulose and 2%w/v PEG 1540 
in the given solvent system. 
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6.2.3 Preparation of solvent-cast membranes 
The solution of ethylcellulose (5% w/v) and PEG 1540 (2% w/v) in equal proportions 
of isopropanol-acetone was prepared and the required amounts were cast on clean 
glass plates and allowed to dry. The hardened membranes were removed and cut into 
round (20 mm) disks. The thicknesses were recorded and selected samples exposed 
to the various dissolution media. 
6.2.4 Dissolution studies 
The dissolution tests were conducted using the USP paddle method (apparatus II) at 
50 rpm, and 900 mL of dissolution fluid at 37 ± 0.2°e. Five coated tablets were tested 
individually in dissolution media at pH 1.2 (HCl). Further dissolution studies were 
made in phosphate buffers at pH 5.4 and 7.4. Dissolution rate measurements were 
carried out by passing filtered dissolution medium through a spectrophotometer cell 
and monitoring absorbance at 271 nm. Samples of the medium (5 mL) were removed 
at 1 h intervals for 12 h, and filtered through a 0.22.um Millipore filter. The volume 
was restored by adding fresh dissolution medium at 37°C. The pH of the dissolution 
medium was checked at the end of each hour during the dissolution run. No significant 
change in the pH of the test medium occurred when phosphate buffers were used. 
The hydrochloric acid medium increased from an initial pH 1.2 to a final pH 2.1. 
6.2.5 Administration and blood sampling 
Rabbits fasted overnight with water freely available. One theophylline coated tablet 
was admiI)istered to the rabbit via a plastic catheter sufficiently far into the oropharynx 
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to avoid ejection (Venho & Eriksson, 1986). Blood samples (2.0 to 3.0 mL) were drawn 
from the marginal ear vein at suitable time intervals. The serum was separated and 
stored at -18°C before theophylline concentrations were measured by fluorescence 
polarization immunoassay (TDX-analyser system, Abbott Laboratories). 
6.3 RESULTS AND DISCUSSION 
For drugs formulated as modified-release dosage forms, it is appropriate to assess the 
extent to which pH of the dissolution medium affects release, and whether such effects 
are significant. 
Drug release profiles from the coated mini-tablets in various dissolution media over 
a period of 12 h, under identical hydrodynamic conditions, are shown in Fig. 6.1. 
The rate of dissolution of theophylline at pH 1.2 is substantially greater than the rate 
of dissolution in phosphate buffers. Theophylline solubility is pH-independant and 
its pKa is 8.6 (Cohen, 1975) so pH-dependant release of the drug was not expected 
in the pH range studied. Although a lag period of 15 to 25 min to commencement of 
dissolution was observed in all the dissolution media, drug release into media con-
taining phosphate ions (PH 5.4 and 7.4) was slow over the entire range of sampling 
times (Fig. 6.1). The maximum amount of drug released after 12 h was approximately 
20 and 30% of total drug content of the tablet in pH 5.4 and 7.4, respectively. When 
quality control limits are defined for a finished product specification, these should 
normally ensure that at least 80% of the active content is released within a narrow 
"release window" (Cartwright, 1987). 
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Fig. 6.1 Release profUes of slow-release theophylline mini-tablets coated with ethylcellulose-PEG in 
hydrochloric acid pH 1.2 (+ ), phosphate buffers pH 7.4 (* ), and pH 5.4 (0), respectively. Each 
value represents the mean ± s.e.m. (n = 5) 
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Fig. 6.2 Dissolution profiles of fUm coated slow release theophylline mini-tablets in hydrochloric acid 
dissolution medium (first hour) and in phosphate buffers (second hour and thereafter). Data are 
expressed as mean ± s.e.m. (n = 5). 
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The results of the present investigation with film coated mini- tablets provide further 
evidence of the substantial effect that different dissolution media may have on both 
the rate and the extent of dissolution (Fig. 6.1) 
While retarded drug dissolution is intended for the controlled release tablets, too slow 
a release process may result in poor bioavailability. Fig. 6.2 shows the results of an 
attempt to simulate an initial 1 h exposure of the tablet to gastric fluid (PH 1.2), 
followed by exposure to intestinal fluid of pH 5.4 and pH 7.4. Both buffers inhibited 
the release process in comparison with media containing hydrochloric acid. Dissol-
ution studies were also performed using water and dilute hydrochloric acid (PH 6) to 
evaluate the influence of pH on the dissolution rate in the absence of phosphate ions. 
The release profiles obtained were within 5% of data obtained for dissolution rates 
at pH 1.2 (hydrochloric acid), with no change being observed in the pH of the 
dissolution medium during the test. In an attempt to establish that the cause of 
inhibition in the release process was not a lack of channel formation, solvent-cast films 
of the coating solution were prepared. Scanning electron micrographs confirmed that 
pores were formed in the coating film on exposure to the various dissolution media 
investigated and that pore formation was not affected by phosphate ions. The size 
and size distribution of channels formed in the membranes exposed to both dilute 
hydrochloric acid (PH 1.2) and phosphate buffers (PH 5.4 and 7.4) were similar. Thus 
retardation of dissolution in phosphate buffer apparently cannot be ascribed to an 
effect of phosphate ions on the coating film. 
An investigation was initiated to establish the in vivo bioavailability and the influence 
of gastrointestinal fluid on drug delivery and absorption, using the rabbit as an animal 
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model. Fig. 6.3 shows the serum concentration-time profile of theophylline adminis-
tered as a slow-release, coated mini-tablet. Comparison ofthe area under this CUIVe 
with data following intravenous infusion demonstrated that the orally administered 
dose was 95% bioavailable. This clearly indicates that phosphate buffered media are 
not suitable dissolution fluids for the in vitro screening of release profiles of coated 
theophylline tablets. It appears that the rate-determining step for theophylline re-
lease is a transport step, since water channels were formed in the film by each of the 
various dissolution media and the solubility of theophylline was not significantly 
affected by the medium used (see solution properties). This may involve an interac-
tion of phosphate ions with theophylline molecules at the core-coat interface resulting 
in an insoluble complex or large molecular structure in comparison with that arising 
in the presence of chloride ion. This is depicted in Fig. 6.4, showing that the 
dissolution rate may be controlled by a surface reaction. 
SERUM CONCN (mcg/mL) 
12r----------------------------------------------. 
8 
4 
2 4 6 8 24 
TIME (Hours) 
Fig. 6.3 Theophylline serum concentration versus time profLIe following oral administration of 20 mg 
slow release coated mini·tablet to a rabbit. 
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Fig_ 6.4 Schematic representation of proposed interaction of phosphate ions with theophylline at the 
core-coat interface influencing the mass transport phenomenon. 
The classical theory describing dissolution rate in relation to pH and pKa, based on 
the Noyes-Whitney equation, suggests that the dissolution rate per unit area of a weak 
acid is controlled by its solubility, diffusion coefficient and Nernst diffusion layer 
thickness. On this basis, Higuchi et aI., (1958, 1964) developed a theory describing 
the dissolution rate as a combined process of simultaneous chemical reaction and 
diffusion. When the concentration of drug in the film pores approaches saturation 
the reverse process should also be taken into account, that is the simultaneous 
deposition of solid drug (Kallay and Senjkovic, 1987). Conversion of anhydrous 
theophylline into the less soluble hydrated form, and crystallization on the surface of 
the undissolved anhydrous theophylline as a direct surface reaction, may also occur 
(Shefter and Higuchi, 1963; De Smidt et aI., 1987). These processes, as well as 
decreased fluid shear rate over the dissolving surface within the pores, may influence 
mass transport causing less efficient removal of dissolved solute from the vicinity of 
the dissolving surface. This would result in a concentration build-up at the core-coat 
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interface within the pores, conducive to self-association of theophylline molecules (I), 
(Thakkar et aI., 1971). 
CH J 
I 
N 0 t;x;r N "CH H J 
: 0 
. 
I 
Consequently partial supersaturation within the diffusion boundary layer, and 
changes in kinematic viscosity, pH gradient, and hydrodynamic conditions with re-
spect to pore size and diameter, may alter the rate of dissolution and diffusivity of 
drug molecules in the system investigated. The rate limiting step may alternatively be 
attributable to an activated complexation, the stoichiometry of which would depend 
to a large extent on the physiochemical properties of the drug and tablet constituents 
at the core-coat interface. These results emphasise the importance of screening and 
selection of dissolution media in dissolution testing. In vitro dissolution tests do not 
neccesarily give reliable information about the absorption properties of drugs, and an 
animal model thereof is useful for the evaluation of in vivo drug release and sub-
sequent bioabsorption during the development of modified-release dosage forms. 
131 
CHAPTER SEVEN 
IN VIVO EVALUATION OF A THEOPHYLLINE ORAL CONTROLLED RELEASE 
CAPSULE CONTAINING FILM COATED MINI-TABLETS IN BEAGLE DOGS 
7.1 INTRODUCTION 
Sustained release oral dosage forms pf theophylline should provide release properties 
such that peak-trough fluctuations are minimised. The bronchodilating effect is 
closely related to the plasma concentration (Mitenko and Ogilvie, 1973) and concen-
trations between 10 and 20,uglmL are considered best for both therapeutic efficacy 
and freedom from toxicity (Jacobs et ai, 1976). However its pharmacokinetic charac-
teristics are such that plasma levels within the desired range are difficult to maintain. 
There is great inter-individual and age dependant variability in elimination rates 
(Ellis, et al., 1976; Paifsky and Ogilvie, 1975; Jenne et al., 1972) depending upon 
factors such as age, smoking history, diet, disease and concurrent use of other drugs 
(Lefebvre et al., 1988; Ogilvie, 1978). Numerous single-unit and multiple-unit oral 
controlled release dosage forrns have been developed (Gangadharan et al., 1987; 
Lippold and Forster, 1984; de Haan and Lerck, 1986). 
The production and in vitro release of theophylline from mini-tablets film coated with 
polymers were described in chapter four. Hard gelatin capsules containing a certain 
number of mini-tablets film coated with Eudragl?RL and RS 2% w/w were subjected 
to in vivo evaluation in Beagle dogs using both single dose and multiple dose studies. 
The various pharmacokinetic parameters were calculated such as area under the curve 
(AVe), extent of bioavailability (EBA), peak concentrations (Cmax), time to peak (t 
max), dosage form index (DI) and the constancy of serum concentrations. A compari-
son was I,llade with parallel studies using a commercial oral controlled release 
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preparation (Theo-DJ) as well as administration of theophylline anhydrous powder 
enclosed in a hard gelatin capsule. Section 7.2 of this chapter describes a single dose 
bioavailability study of the test capsule, while Section 7.3 describes a multiple dose 
study to steady state conditions. The protocols of these studies were approved by the 
, 
Director of the Provincial Animal C:;entre, Kuils River, Cape Town. 
7.2 SINGLE DOSE BIOAV AILABILITY STUDY 
7.2.1 MATERIALS AND METHODS 
Products tested 
Hard gelatin capsules containing a certain number of film coated mini-tablets (3 mm 
diameter, 15 ± 0.5 mg each) of theophylline manufactured by a process described in 
Chapter four. 
Test unit A: Capsules (size 1) each containing 20 mini-tablets (300 mg theophylline) 
of which 10 were uncoated (immediate release 150 mg) and 10 were coated with 
EudragitIDRS 2% (sustained release 150 mg). 
Test unit B: Capsules similar to test unit A but the sustained release component was 
film coated with Eudragi<?RL 2% w/w. 
Parallel Studies 
Test Unit C: Capsule (size 1) containing 300 mg theophylline anhydrous powder B.P. 
Tablets of a standard marketed controlled release theophylline product (Theo-Dur® 
300mg). 
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Dosing and Blood Sampling 
Four Beagle dogs (1 male and 3 female) weighing 12 - 15 kg (13.78 ± 1.72 kg) were 
used in this cross-over design single dose study on each test unit after a suitable 
wash-out period (14 days). The dogs were fasted for 24 h before administration of the 
first test dose with water ad libitum. ' A test unit was administered between 06hoo and 
07hoo on the day of the study. 
Oral administration of the unit was achieved by opening the mouth of the dog, 
depressing the tongue, placing the unit in the throat region with subsequent adminis-
tration of about 100 mL water, and firmly closing the mouth and blowing air through 
the dog's nose in order to facilitate swallowing (Gangadharan et aI., 1987). The dogs 
received their normal food (commercial brand of dog chunks) on the day of study. 
Blood samples were drawn at 0, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h after dosing. About 
3 - 5 mL of blood were drawn each time from the jugular vein via a teflon 16 G cannula. 
The projecting end of the cannula was sutured to the skin to prevent it from being 
pulled out. The neck of the animal was bandaged to prevent interference. During 
sampling the bandage was removed to facilitate blood withdrawal after ~hich the 
cannula was flushed with heparinised normal saline. The blood samples were allowed 
to stand for one hour, centrifuged and the serum kept frozen ( - 20"C) until analysis. 
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Assay of theophylline in serum 
Theophylline concentrations in serum were determined using a fluorescence immu-
noassay system (TDX Analyser, Abbott). 
Pharmacokinetic Analysis 
The pharmacokinetic parameters relevant to this single dose study include area under 
the curve (AUCo"' OO), peak concentration, time to peak and time for which blood 
levels remain above 7 .ug/mL. The AUCo"' oo was calculated in each case using the 
linear trapezoidal rule. 
Dissolution Studies 
The in vitro dissolution of theophylline from the encapsulated mini-tablets and the 
Theo-Dur 300 tablets was determined by the USP XXI paddle method. The dissolu-
tion medium was distilled water (lL) at 37°C at a paddle speed of 50 rpm (influence 
of pH was not significant on release profiles as has been described in Chapter 6). The 
concentrations of theophylline were assayed by UV spectrophotometry at 271 nm. 
7.2.2 RESULTS 
In vitro dissolution studies 
The dissolution profiles of theophylline from test units A and B and also from 
Theo-Du?3oo mg tablets are shown in Fig. 7.1 a and b. The mini-tablets from test 
units A and B released the drug in excess of 90% over periods of 4 hand 2 h, 
respectively. 
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Fig. 7.1 a and b. Percent theophylline dissolved in vitro from test units A and B and also from Theo-D,Ji!> 
300 mg tablets. 
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The maximum amount of theophylline released in vitro from the Theo-Du~300 tablets 
was about 70% of the amount stated on the label over 12 hours. 
Bioavailability studies 
The mean serum theophylline concentrations CuglrnL) as a function of time in hours 
for each test unit is shown in Fig. 7.2 a and b. Table 7.1 shows the relevant pharrna-
cokinetic parameters after single dosing with each test unit. 
TABLE 7.1 Pharmacokinetic parameters calculated (±S.D.) from the data from four dogs after a single 
oral dose of the test products. 
PARAMETER PRODUcr 
Test unit A Test unit B 
AUC 0-+ 00 (uglmL.h) 88.2 (±19.3) 175.2 (±26.3) 
EBA (test unit C as standard) 0.53 1.05 
Cmax (uglmL) 8.2 (±2.6) 10.7 (±3.8) 
t max (h) 3.0 (±0.6) 5.0 (±0.6) 
Duration above 7/lglmL (h) 2.2 (±1.2) 9.3 (±1.7) 
Test unit A - mini-tablets uncoated and coated with EudragiFRS 2% 
Test unit B - mini-tablets uncoated and coated with EudragirRL 2% 
Test unit C - anhydrous theophylline (300 mg) 
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Test unit C ® Theo-Dur 300 
166.4 118.9 (±22.4) 
1.0 0.71 
20.0 11.9 (±3.6) 
2.0 6.0 (±i.4) 
6.2 7.9 (±1.1) 
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Fig. 7.2 b .......... Test Unit B -- Theo-Duf'il300 
Fig. 7.2 a and b. Mean theophylline concentrations as a function of time in serum following peroral 
administration of 1 unit of each of the test units A, Band C and Theo-D~. (n = 4 except for C 
which is the mean of duplicate studies). The composition of the test units are described in the text. 
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7.2.3 DISCUSSION 
The pharmacokinetic parameters and serum concentration profile shows that test unit 
B compares favourably with that of the commercially available controlled release 
product (Theo-DuiID300 mg). The AVC of the test unit B (175.2 ,..glmLh) was 
significantly greater than that ofTheo-Du?(118.9 ,..glmL.h). The time to peak (t max) 
was smaller for test unit B (5h) than Theo-DtJ'il(6 h) which means that the onset of 
action for the test unit was faster. Although the Cmaxvalue for Theo-DJl'was greater 
than that for test unit B (11.9 "glmL and 10.7 "glmL respectively), the test unit over 
the time period 2 to 10 h produced more constant serum concentrations with a range 
of 4.7 - 10.7 "glmL while the range for Theo-Du!il.vas 2.4 - 11.9 "glmL. In addition 
the time period over which the serum levels remained above 7 "glmL (assumed level 
above which the drug will produce a therapeutic effect) was longer for the test unit B 
compared to Theo-DufB!(9.3 h and 7.9 h respectively). 
The faster onset of action by test unit B was probably achieved by the uncoated 
mini-tablets in the capsule which provided the immediate release component. This 
immediate rise in blood levels occurred over the first 3 hours after dosing and it is 
worthy of note that a similar rise occurred with test unit A in which the immediate 
release component was identical. 
Test unit A contained mini-tablets coated with Eudragi~S 2% combined with an' 
immediate release component of uncoated mini- tablets. The immediate release 
portion caused the serum level to rise to 8 "glmL within 3 hours but thereafter levels 
dropped steadily to just above 3 "glmL after 12 hours. The AVC""''' for this test unit 
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was 88.2 ,uglmL.h which was lower than that for Theo- Our® which in tum was 
significantly lower than the AVC for test unit B. 
®\ 
By virtue of the content of quaternary aminonium groups it contains, Eudragit RL 
® 
films are, in contrast to Eudragit RS, freely permeable to water and dissolved drugs 
so that theophylline release is relatively modestly retarded. The in vitro dissolution 
® . 
profile for mini-tablets coated with Eudragit RL 2% w/w confirms this fact (Fig. 7.1). 
Although test unit B (mini-tablets film coated with Eudragif@RL 2%) released 
theophylline in vitro to the extent that over 90% was released in 2 hours the release 
profile in vivo was much slower and test unit B produced serum concentrations within 
the therapeutic range over a period of about 9 hours. There is a distinct lack of in vitro 
- in vivo correlation data and these findings are in general agreement with the 
conclusions drawn in Chapter 6. The parallel study using theophylline anhydrous 
powder 300 mg (test unit C) produced a C max of 20 ,uglmL and a t max of 2 hours. 
After peak concentration serum levels dropped rapidly to 3.4,uglmL after 12 hours. 
The AVc""''' was 166.4 ,uglmL.h and by comparison with the AVC for test unit B 
(175.2,uglmL.h) there is no significant difference between test units Band C. (EBA 
is close to 1). Therefore the degree of theophylline absorption from test unit B is 
similar to that from capsules containing 300 mg of anhydrous theophylline powder. 
However the extent ofbioavailability (EBA) of test unit B (1.47) is significantly higher 
® 
compared to the commercial marketed product (Theo-Our). This indicates that test 
unit B liberates the total amount of its theophylline content and is more bioavailable 
® 
compared with Theo-Our 300 (which only releases 70% of its theophylline content in 
12 h). In summary this study has shown that the test unit B, a capsule containing 
® 
uncoated mini-tablets and mini-tablets film coated with Eudragit RL 2% w/w (each 
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providing 150 mg theophylline as immediate release and controlled release respec-
tively), can offer advantages over the commercially available product. 
7.3 MULTIPLE DOSE BIOAVAILABILITY STUDY 
7.3.1 MATERIALS AND METHODS 
This multiple dose study was conducted over 4 days (96 h) in four Beagle dogs which 
had not been used in any other test over the previous 14 days. The dogs (1 male and 
3 females) weighed 12 - 15 kg (13.78 ± 1.72 kg). The dogs were fasted for 24 h prior 
to administration of the first dose. The dosage units consisted of capsules each 
containing 14 film coated mini-tablets providing a dose of2oo ± 5 mg of theophylline 
(this dose provided blood levels within the therapeutic range after 4 half lives). Each 
capsule (size 1) contained 7 uncoated mini-tablets (0.3 cm in diameter, 15 ± 0.5 mg 
in weight) and providing 100 mg of drug as an immediate release component. The 
other 7 mini-tablets of similar dimensions were film coated with an amount of 
Eudragit~L 2% w/w, the methods of manufacture and coating, as well as the 
dissolution profiles, are described in chapter four. The dissolution profile of the 
dosage unit was identical to the profile for test unit B given in Fig. 7.1 a. The film 
coated mini-tablets comprised the 100 mg of controlled release drug. 
The first dose unit was administered between 06hOO and 06h45 on the first day of the 
study. Dosing of each dog was staggered at 15 minute intervals so as to facilitate 
subsequent blood sampling. Oral administration of the unit was achieved by opening 
the mouth of the dog, depressing the tongue, placing the capsule in the throat region 
with subsequent administration of about 100 mL of water. The mouth was firmly 
closed an9, when necessary, air was blown through the dog's nose in order to facilitate 
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swallowing (Gangadharan et aI., 1987). The second, third, fourth, fifth, sixth and 
seventh doses were administered in the same manner every 12 hours after the first 
administration, corresponding to 12, 24, 36, 48, 60 and 72 h .. Normal feeding was 
resumed after the first dose until 72 h when food was again discontinued for a period 
l 
of 24 h. Blood samples were drawn ,at 0, 2, 4, 6, 8, 10, 12,24,36, 48, 60, 72, 74, 76, 78, 
80, 82, 84, 87 and 96 hours. About 3 - 5 mL of blood were drawn each time from the 
cephalic veins in the forelegs of the dogs. The blood samples were allowed to stand 
for one hour, centrifuged and the serum kept frozen until analysis. 
Determination oCExtent oCBioavaiiability (EBA) 
Parallel studies were carried out using the same four dogs (after a wash-out period of 
14 days) and a further two dogs. These were single dose studies involving the oral 
administration of theophylline anhydrous powder (200 mg) enclosed in a hard gelatin 
capsule to two dogs, another two received orally a commercial controlled release 
theophylline tablet (Theo-Du~200 mg), while the third pair received the test capsule 
(200 mg). In these parallel studies blood was sampled every hour until 12 h and then 
at 24 h. In this case blood was drawn each time from the jugular vein via a teflon 16 
G cannula and flushed with heparinised normal saline. The parallel studies were 
performed so that the extent of bioavailability (EBA) of the test unit may be calcu-
lated. 
Theophylline Determination in Serum 
The concentrations of theophylline in serum were determined using a fluorescence 
immunoassay system (TDX Analyser, Abbott). The area under the curve (AUC) was 
caIculateq in each case by the linear trapezoidal rule. 
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7.3.2 RESULTS 
Serum levels of theophylline (ugiroL) following the first and seventh doses ofthe dose 
unit are shown individually for the four dogs in Fig. 7.3. The area under the curve 
(AVeo"'",) for each dog after single dose treatment, the AVe~n"'Tn + lethe Ave 
during one dosing interval at steady'state) after multiple dosing, and the dosage form 
index (DI) are shown in Table 7.2. The DI is defined as the ratio of the maximum to 
minimum concentrations of the drug in serum within each inter- dose interval (in h),~, 
during repetitive administration of the dosage form in the quasi-steady state 
(Theeuwes and Bayne, 1977). Fig. 7.4 shows the mean serum theophylline concen-
tration ± S.D. versus time following the first and seventh doses to the dogs (n = 4). 
Table 7.3 shows the mean AUCo"'", determined during the parallel studies after 
single dose p.o. treatment with theophylline powder and the commercial product 
(Theo-Du~. The relative bioavailability (EBA) is calculated with reference to both 
the Theo-Duf'Yand the theophylline powder. 
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Fig. 73 Individual theophylline concentrations as a function of time in serum following peroral 
administration of 1 unit (200 mg) of experimental controlled release dosage form every 12 h in 4 Beagle 
dogs. 
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Fig. 7.4 Mean theophylline concentrations ±S.D. as a function of time in serum following peroral 
administration of 1 unit (200 mg) of experimental controlled release dosage form every 12 h in Beagle 
dogs (n = 4). 
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TABLE 7.2 PbarmacokJneUc parameters after single and multiple dose administration of capsule 
dosage unit (200 mg) to Beagle dogs. 
Single Dose Multiple Dose 
Dog f3 AUC°-+" AUCTn-+TD + 1 AUC°-+" • D.1. 
[(uglmL)b] [(uglmL)b] AUCTD-+Tn + 1 
A 0.041 154.30 181.7 0.85 1.45 
B 0.037 236.52 162.6 1.45 1.62 
C 0.047 51.52 1913 0.27 2.04 
D 0.040 141.21 113.9 1.24 2.63 
Mean 0.041 145.89 162.38 0.95 1.73 
S.D. 0.00419 75.75 34.45 0.52 0.53 
S.E.M. 0.00296 53.56 24.36 037 037 
C.V. 10.22 51.92 21.22 54.74 30.64 
C. V. = coefficient of variation 
TABLE 73 The extent ofbioavallabillty for the capsule dosage unit containing mini-tablets, Theo-Dur" 
and theopbylline powder. 
Test Unit 
( mini-tablets) 
Mean AUCo"'" 145.89 
EBA (Theophylline powder as standard) 1.09 
EBA (Theo-Duras standard) 1.48 
7.3.3 DISCUSSION 
Theo-Dur" 
98.55 
0.74 
1.0 
Theophylline 
powder 
1.0 
1.35 
The theophylline serum concentration as a function of time for each dog following 
oral administration of 7 dose units of the experimental product over 96 h are shown 
145 
in Fig. 7.3. There is considerable variation in serum levels from dog to dog, particularly 
in the case of Dog Cwhere in the first 12 h the serum level never exceeded 3.0.uglmL 
compared to Dog B where the concentration reached as high as 13.0 .uglmL after 10 
hours. Even at steady state conditions (after 72 h and seventh dose) this variability 
persisted although to a smaller exte,nt. 
With two dogs (B and D) there was a relatively small difference between peak 
concentrations (C max) during the first 12 h compared with that during the last dosage 
interval, whereas with the other two (dogs A and C in particular) the higher C max 
during the last dosage intervals was significant. It is also noteworthy that the time to 
peak (t max) during the first 12 h varied considerably (2 h to 10 h). On the other hand 
the serum concentration curves from 72 h to 96 h show that the t max was reasonably 
consistent (at 76 h) although the C max value itself was variable. In one case (dog C) 
the C max at 76 h exceeded 20 .uglmL but no noticeable signs of theophylline toxicity 
occurred. 
Higher peak concentrations after the seventh dose was expected since multiple dosing 
with equal dose sizes at equal dosing intervals can produce accumulation in certain 
individuals. 
However it is apparent that dose dependancy is absent (ie. no enzyme induction or 
inhibition occurs) since Table 7.2 shows that the mean AUC during any dosing interval 
on multiple dosing (AUC-ro-+-ro + 1) at steady state is almost the same as the mean 
AUC after single dose administration (AUC°-+ OO). The ratio of the mean AU-
C°-+ oo /AUe°-+ro + 1 is approximately 1 (0.95 ± 0.52). This ratio in individual dogs 
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does vary however(fable 7.2). For Dogs A and D this ratio is close to 1 (0.85 and 1.24 
respectively) whereas Dog B and C are significantly different. 
The mean DI for the experimental dosage unit was calculated to be 1.73 ± 0.53 
(obtained from the ratio of CSS max to CSS min) which is small enough t(') ensure that 
maintenance of blood concentrations in the therapeutic range over a 12 h dosage 
interval is possible. 
The determination of the EBA and the AUc""''''' was obtained after single dose 
cross-over parallel studies (fable 7.3). As shown in Table 7.3 there is little difference 
between the AUC for the test dosage unit and the theophylline powder indicating that 
there is as much absorption of theophylline from the test capsule (mini-tablets) as 
there is from the capsule containing theophylline powder. The EBA of the commer-
cial product is only about 70% of that for the test dose uni,t and hence the controlled 
release capsule containing film coated mini-tablets has a distinct advantage over 
Theo-DJlin that it has greater bioavailability. This is consistent with in vitro dissol-
ution studies carried out in earlier work which showed that about 70% ofthe drug was 
released in 12 h from Theo-Du~compared with over 95% release from mini- tablets 
film coated with EudragifuL 2%. 
From the data presented in this chapter it appears that the mini- tablet formulation 
demonstrates complete release of theophylline and offers the advantage in that 
precise dosage adjustment can be made. 
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CHAPTER EIGHT 
CONCLUSIONS 
Theophylline is still an important drug used in asthma therapy. Its mechanism of 
action is complex and there is much which needs to be more precisely understood 
(Barnes, 1989). One of the problems associated with its use is the'rather small 
therapeutic range made more diffiCult by the fact that the same dose causes consid-
erable variation in plasma concentrations in different patients. Conventional oral 
dosage forms of theophylline would have to be administered at short frequent time 
intervals in small doses in order to maintain therapeutic concentrations. This would 
be greatly inconvenient to the user and produce poor patient compliance. The 
introduction of oral sustained release theophylline preparations has brought about a 
radical change to the extent that the risk of high peaks and low trough values has been 
substantially reduced. However the cost of manufacturing many of the recently 
developed novel sustained release drug delivery systems is relatively high. In times 
when health service costs are escalating, the development of simple inexpensive, yet 
effective, dosage forms are of great economic importance. 
Although theophylline is by no means a new drug candidate, preformulation studies 
were carried out to generate certain physicochemical parameters of theophylline 
anhydrous which could provide a basis for the design and development of an appro-
priate controlled release dosage form of the drug. Information relating to the solu-
bility and dissolution rate of the drug was considered most important for this type of 
dosage form. Theophylline is only slightly soluble in water yet it is rapidly and 
completely absorbed from uncoated tablets, but absorption is slower and may be 
incomplete from sustained release preparations. Studies showed that there were 
significant differences in the dissolution rate depending on the shape and size of the 
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individual drug particles. However in slow release dosage forms these differences 
would have little significance over 12 h time periods. The dissolution rate could be 
greatly reduced in the presence of water-insoluble polymers. ·The slowly dissolving 
drug could be completely absorbed at a controlled rate. 
Initially granules of theophylline were produced by wet granulation techniques. The 
binder which provided sufficient adhesive strength to produce a hard granule at a 
relatively low concentration was sodium carboxymethy1cellulose. The granules were 
film coated using the upward spray method. This method was utilised because the 
granule bed weight was small and to ensure that the atomising spray nozzle remained 
in immediate contact with the fluidising bed. The coating conditions were carefully 
optimised so as to ensure that the coating process was reproducible. Subsequent in 
vitro dissolution studies demonstrated that the drug release rate could be regulated 
by inclusion of a water-soluble polymer (PEG 1540) in the insoluble coating material 
(ethy1cellulose), and also by varying the amount of coating material on the granules. 
It has been shown that almost constant release can be achieved from selected 
quantities of granules coated with varying amounts of polymer enclosed in hard gelatin 
capsules. However substantial proportions of the drug remained unreleased from the 
granules, due probably to their highly irregular shape and consequent non-uniform 
coating thickness. 
Mini-tablets were manufactered in order to overcome the problems of drug retention 
and irregular release resulting from the non- uniformity of the granule shape and 
coating thickness. By contrast these mini-tablets are each identical in size, shape and 
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weight. However the amount of coating around each mini-tablet would only be 
uniform if optimal and reproducible coating conditions were maintained during the 
upward spray f1uidised bed coating process. A diagrammatic comparison of the 
appearance of a coated granule and mini-tablet in cross sectional view is shown in Fig. 
8.1. 
Fig. 8.1 Pores and crevices of a granule 
which may be filled over with coating 
material. Uneven coating results in 
irregular release. 
Smooth and regular shaped mini-tablet 
more evenly coated. Drug release is 
reasonably consistent. 
The mini-tablets film coated with Eudragi~L2% consistently released up to 95% of 
their total theophylline content both in vitro and in vivo. In contrast to the granule, 
the more evenly coated mini-tablet is less likely to possess patches of thinner coating 
through which more rapid release would readily take place. It was found therefore 
that less coating material was required for the mini-tablet to provide the same release 
rate as that obtained from granules. This effect was so marked that mini-tablets coated 
with ethyl cellulose required the inclusion of a water- soluble channelising agent to 
promote release. Dissolution profiles could be varied at will by careful adjustment of 
the proportionate number of encapsulated mini-tablets with various amounts of 
polymeric coating. 
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Storage of film coated mini-tablets in environments where they will be exposed to 
different temperatures and relative humidities for prolonged time periods was carried 
out to specifically establish whether the film coatings would· retain their integrity 
under conditions of stress. It is a possibility that coatings could crack or split producing 
, 
significantly faster drug release raters. The studies demonstrated that film integrity 
was maintained for periods even up to 180 days. However drug release was signifi-
cantly impeded presumably due to some physicochemical changes taking place in the 
polymeric coating material. The nature and extent of these changes is not precisely 
known and further work could be undertaken to investigate the mechanisms produc-
ing inhibition of release. However, preliminary investigations carried out involving 
thermogravimetric analysis has shown that moisture loss is not responsible for re-
tarded release. Although in vitro drug release is significantly impeded after storage, 
it is not known at this stage whether in vivo release would be similarly affected 
particularly in view of the poor in vitro/in vivo correlations demonstrated in this work 
for film coated mini-tablets. 
In addition it has been shown that certain in vitro dissolution media recommended for 
use in the USP dissolution testing method cannot be relied upon to predict-actual in 
, 
vivo absorption of theophylline from film coated mini-tablets. The transport of 
theophylline through the coating membrane is drastically reduced if the dissolution 
medium is buffered with phosphate ions. Therefore it is reasonable to assume that 
the transport mechanisms of other drugs from this, as well as other different formu-
lations, may be also affected producing either inhibition or even enhancement of drug 
release depending on the composition and nature of the dissolution medium. It is 
vitally important therefore, when comparing dissolution profiles of the same dosage 
, 
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form, to pay particular attention to the precise conditions under which the in vitro 
dissolutions tests were conducted. In vitro dissolution tests do not necessarily give 
reliable information about absorption properties of drugs, and an animal model 
therefore is useful for the evaluation of in vivo drug release and bioabsorption during 
the development of modified-release dosage forms. 
The in vivo evaluation of the capsules containing uncoated and film coated mini-ta-
blets (Eudragifu 2%) in Beagle dogs demonstrates that satisfactory release of the 
drug is provided. Moreover precise dosage titration may be achieved for a particular 
individual by selecting and adjusting the exact number of mini- tablets in the capsule. 
There was however poor correlation between in vitro and in vivo release of theo-
phylline from the film coated mini-tablets and prediction of in vivo release could not 
be made from in vitro dissolution data. 
The controlled release capsules containing film coated theophylline mini-tablets 
(Eudragii\L 2%) are easily produced utilising standard equipment. The film coating 
material was homogenous and filling machines can simply deliver a definite number 
of mini-tablets into the open capsule body. Production costs would hence be relatively 
low. This work has demonstrated the bioavailability of this mini-tablet capsule dosage 
form in Beagle dogs but further work could be directed at evaluating this dosage form 
in human volunteers. 
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